Role of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer

Wei Zhou; Adrian Lim; Mouad Edderkaoui; Arsen Osipov; Heshui Wu; Qiang Wang; Stephen Pandol

doi:10.7150/ijbs.83586

. 2024 Jan 1;20(1):15–28. doi: 10.7150/ijbs.83586

Role of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer

Wei Zhou ^1,², Adrian Lim ¹, Mouad Edderkaoui ¹, Arsen Osipov ¹, Heshui Wu ^2,^✉, Qiang Wang ^1,^✉, Stephen Pandol ^1,^✉

PMCID: PMC10750275 PMID: 38164167

Abstract

Although recent advances in cancer treatment significantly improved the prognosis of patients, drug resistance remains a major challenge. Targeting programmed cell death is a major approach of antitumor drug development. Deregulation of programmed cell death (PCD) contributes to resistance to a variety of cancer therapeutics. Yes-associated protein (YAP) and its paralog TAZ, the main downstream effectors of the Hippo pathway, are aberrantly activated in a variety of human malignancies. The Hippo-YAP pathway, which was originally identified in Drosophila, is well conserved in humans and plays a defining role in regulation of cell fate, tissue growth and regeneration. Activation of YAP signaling has emerged as a key mechanism involved in promoting cancer cell proliferation, metastasis, and drug resistance. Understanding the role of YAP/TAZ signaling network in PCD and drug resistance could facilitate the development of effective strategies for cancer therapeutics.

Keywords: Programmed cell death, YAP/TAZ, Apoptosis, Ferroptosis, Autophagy, Drug resistance

Current landscape of cancer therapy and challenge

Surgery combined with chemotherapy or radiotherapy are currently the first-line treatment modalities for localized tumors. However, many patients suffer from tumor recurrence and development of acquired resistance despite success in initial treatment ¹^,². Most patients with advanced solid tumors, such as hepatocellular carcinoma, pancreatic adenocarcinoma and glioblastoma, show intrinsic resistance to chemotherapy and other antitumor agents at the initial stage ³^-⁵. Drug resistance in cancer is multifaceted and can be mediated by mechanisms that impact on drug availability, cell proliferation and response to DNA damage or metabolic pathways. Deregulation of cell death signaling represents an important mechanism of drug resistance because most of the anti-tumor therapy agents aim to trigger programmed cell death ⁶. Thus, understanding the signaling pathways involved in regulating PCD and drug resistance can provide insights into development of new therapeutic targets.

The Hippo-YAP signaling pathway

The Hippo-YAP signaling plays an important role in aspects of malignant transformation, including cell proliferation, tumor progression, metastasis, and drug resistance ⁷^-¹⁰. YAP and its paralog TAZ are the main downstream effectors of the Hippo-YAP pathway and act as a transcriptional coactivator ¹¹^-¹³. The YAP signaling can translocate into the nucleus and mediates gene transcription by binding to transcription factors, such as the TEA domain family (TEAD) proteins ¹². YAP exhibits oncogenic activities ¹⁴^,¹⁵ and is upregulated in most solid tumors ¹⁶^-²². YAP signaling target genes participate in regulation of development, cell proliferation, migration and survival ²³^-²⁷.

YAP signaling is responsive to intercellular adhesion, cell density, and mechanical stiffness of the extracellular matrix ⁷^-¹⁰. YAP can be negatively regulated by a cascade of phosphorylation events that are mediated by mammalian Ste20-like kinases1/2 (MST1/2, the mammalian homolog of Hippo) and large tumor suppressor 1/2 (LATS1/2) ¹¹^,²⁸^,²⁹. The scaffold proteins of adherens junctions, such as NF2 or KIBRA/WWC1, can recruit MST and LATS kinases to the plasma membrane and mediates their activation ³⁰^-³³. The kinase activity of MST1/2 can be activated by binding to the Salvador Family WW Domain Containing Protein 1 (SAV1), a scaffold protein that also forms a complex with LATS1/2¹¹^,²⁸^,²⁹^,³⁴. The Ras Association Domain Family Members (RASSFs) can also associate with MST1 and enhance its kinase activity ³⁵^-³⁷.MST1/2 subsequently activates LATS1/2 by phosphorylating LATS1/2 and its regulatory protein Mps one binder kinase activator-1 (MOB-1) ³⁸^,³⁹. In parallel to MST1/2, the MAP4K family kinases can also phosphorylate and activate LATS1/2 ⁴⁰^-⁴². The activated LATS1/2 then phosphorylates YAP/TAZ ⁴³^,⁴⁴. The phosphorylated YAP can associate with the 14-3-3 proteins and is rendered transcriptionally inactive due to retention in the cytoplasm ⁴⁵^,⁴⁶. Alternatively, the phosphorylated forms of the YAP/TAZ proteins can also be primed for β-TrCP-mediated ubiquitination and degradation ¹³^,⁴³^,⁴⁷. In addition, YAP can be inactivated by binding to a series of proteins, such as angiomotin, Protein Tyrosine Phosphatase Non-Receptor Type 14 (PTPN14) and tight junction protein zonula occludens ⁴⁸^-⁵¹. Conversely, YAP can be activated by G-protein coupled receptors or the mevalonate pathway through rho GTPase signaling ⁵²^-⁵⁵. Epithelial cell transforming 2 (ECT2), a guanine nucleotide exchange factor for Rho-like GTPases that activates Rho signaling, can positively regulate YAP function and is reciprocally regulated by YAP ⁵⁶. The SRC family tyrosine kinases and the c-ABL kinase have also been reported to promote YAP signaling by tyrosine phosphorylation of YAP ⁵⁷^-⁵⁹.

In addition to phosphorylation, YAP signaling can be regulated by other forms of post-transcriptional modifications. For example, YAP can be methylated by the SET Domain Containing 1A (SET1A) methyltransferase complex, which promotes its oncogenic activities by blocking nuclear export ⁶⁰. YAP can also be modified by O-GlcNAcylation that prevents its phosphorylation by LATS1, leading to nuclear localization and enhanced tumorigenic functions ⁶¹. Moreover, O-GlcNAcylation of LAST2 has been reported to cause YAP/TAZ activation and promote tumor growth ⁶². Acetylation of LAST1 inhibits YAP phosphorylation and degradation and promotes cancer cell invasion and growth ⁶³. Thus, post-transcriptional modification is an important mechanism in regulating YAP signaling.

YAP signaling activation and Drug Resistance

A growing number of studies reveal that activation of YAP signaling contributes to resistance to chemotherapy, targeted therapy and immunotherapy.

(1) YAP signaling and Chemotherapy

DNA-damaging agents, such as doxorubicin, irinotecan, oxaliplatin, and cisplatin, aim at DNA replication as a target to induce cytotoxic effects and are widely used in the clinics. YAP signaling is closely linked to the resistance of DNA-damaging agents. YAP is a key regulator of doxorubicin resistance in thyroid cancer and is regulated by tripartite motif-containing protein 11 (TRIM11) ⁶⁴. Overexpression of YAP confers resistance to doxorubicin by regulating bcl-xl ⁶⁵. Activation of YAP also promotes doxorubicin chemoresistance in cholangiocarcinoma and osteosarcoma cells ²⁰^,⁶⁶. Inhibition of YAP enhances oxaliplatin and irinotecan sensitivity ⁶⁷^,⁶⁸. YAP activation induces cisplatin resistance in small cell lung cancer (SCLC) cells ⁶⁹, whereas knockdown of YAP increases the sensitivity of cisplatin in ovarian cancer cells ⁴⁸^,⁷⁰. In addition, overexpression of TAZ is involved in regulation of cisplatin resistance of cervical, gastric, lung and ovarian cancer ²²^,⁷¹^-⁷³.

Agents inhibiting metabolic pathways represent another major class of chemotherapy agents that can sabotage DNA or RNA synthesis and inhibit cell division and survival. Gemcitabine and 5-fluorouracil (5-FU) are cytidine and uracil nucleoside analogues, respectively, which are widely used for the treatment of multiple tumors. Knockdown of YAP enhances gemcitabine sensitivity ⁷⁴. In addition, high levels of YAP are associated with poor survival in patients following 5-FU treatment, which is accompanied with an increase of M2 polarization of macrophage in the tumor ⁷⁵. However, a recent study reported that overexpression of an activating mutant form of YAP appears to enhance cancer cell sensitivity to gemcitabine and 5-FU, by reducing drug efflux ⁷⁶. It should be noted that these findings remain to be corroborated with knockdown studies.

Anti-microtubule agents block mitosis by interfering with microtubules dynamics and induce apoptosis. Examples of classical anti-microtubule agents include taxanes (paclitaxel and docetaxel), which are widely used for the treatment of breast, ovarian, gastric, pancreatic and colorectal cancer ⁷⁷. YAP has been reported to confer resistance to paclitaxel in cancer cells ⁷⁸^,⁷⁹. Similarly, TAZ and TAZ/TEAD-mediated expression of Cyr61 and CTGF are also vital in paclitaxel response ²¹^,⁸⁰. Moreover, down-regulation of YAP has been found to enhance sensitivity to docetaxel ⁸¹. The mechanism by which YAP signaling modulates resistance to taxanes may involve YAP- and TEAD-regulated expression of ATP Binding Cassette Subfamily B Member 1 (ABCB1), which encodes the multidrug resistance protein 1 and is implicated in paclitaxel resistance ⁸². In addition, YAP mediates the expression of an array of mitotic genes and deregulation YAP signaling can lead to aberrant mitotic checkpoint control ⁸³^,⁸⁴. The mitotic regulator cyclin-dependent kinase 1 (CDK1) phosphorylates YAP in response to paclitaxel-induced G₂/M arrest ⁸⁵. But its role in drug resistance remains to be clarified.

Thus, an increasing body of evidence indicate that activation of YAP signaling results in chemoresistance and inhibition of this pathway may enhance cancer cell sensitivity to chemotherapeutic drugs. Targeting YAP signaling pathway represents a potential strategy to overcome chemotherapy resistance. Indeed, the combination of YAP inhibitor with chemotherapy has shown increased efficacy in chemo-resistant tumors ⁸⁶^,⁸⁷.

(2) YAP signaling and Targeted Therapy

Targeted therapy is designed to block molecules and pathways that are vital for cancer cell proliferation, survival, invasion and metastasis and rewrote the paradigm of leukemia treatment ⁸⁸. Targeted therapy for epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER-2), vascular endothelial growth factor receptor (VEGFR), and BRAF have been developed for clinical use ⁸⁸. In this section, we will briefly discuss how YAP signaling regulates targeted therapies.

BRAF, a serine/threonine protein kinase of the RAF kinase family, is a key regulator of the MAP kinase signal transduction pathway. BRAF gene mutations occur in a large percentage of cancers, including approximately 50% of melanomas, 20% to 40% of thyroid cancers, and 10% of colorectal cancers ⁸⁹. Although BRAF inhibitors have shown benefit in melanoma patients with the oncogenic BRAF^V600E mutant, acquired drug resistance remains a significant obstacle ⁹⁰. NF-2, a negative regulator of YAP signaling, was identified as a gene associated with cancer cell sensitivity to BRAF inhibitor, which indicates that YAP signaling could participate in BRAF inhibitor resistance ⁹¹. In a separate study, activation of YAP was shown to induce resistance to BRAF inhibitor in melanoma cells through the actin dynamic regulator testis associated actin remodeling kinase 1 (TESK1) ⁹². In addition, YAP confers immune evasion in BRAF inhibitor resistant melanoma cells by promoting PD-L1 expression, which can be targeted by immune checkpoint therapy ⁹³. This finding suggests that the combination of BRAF inhibitor with immunotherapy may represent a viable approach to treat BRAF inhibitor resistant melanoma.

EGFR is a receptor tyrosine kinase that is frequently mutated in many tumors ⁹⁴. Small-molecule tyrosine kinase inhibitors (TKIs) for EGFR have shown efficacy in treatment of EGFR-mutated tumors ⁹⁵. However, resistance remains a problem for clinicians. Numerous studies have indicated that activation of YAP/TAZ is widely associated with in EGFR TKI resistance ⁹⁶^-⁹⁸. YAP regulates epithelial-to-mesenchymal transition (EMT)-induced resistance to EGFR TKI in non-small cell lung cancer (NSCLC) via FOXM1/SAC pathway ⁹⁹. YAP could also mediate EGFR TKI-resistant through upregulation of AXL receptor tyrosine kinase ¹⁰⁰ or the autophagy mediator p62¹⁰¹. Combination of YAP inhibitor and EGFR TKI improved response in EGFR inhibitor resistant NSCLC ¹⁰².

YAP signaling is also implicated in resistance to targeted therapies for HER-2, MEK, RAS, ALK and BET inhibitors. YAP1 dephosphorylation and TEAD2 overexpression are closely related to trastuzumab resistance by regulating cytokines like CCL5 in HER-2 positive breast cancer cell lines ¹⁰³. YAP deletion sensitizes the MEK inhibitor trametinib by depletion of MYC/MYCN and E2F transcriptional output in neuroblastoma cells ¹⁰⁴. Dasatinib can enhance the antitumor effect of trametinib in KRAS-mutant cancer models by inhibiting the expression of TAZ protein ¹⁰⁵. YAP activation promotes resistance to ALK-TKI through induction of p21 expression ¹⁰⁶. TAZ nuclear localization and transcriptional activity induces resistance to inhibitors of BET family proteins ¹⁰⁷. In summary, activation of YAP/TAZ signaling contributes to the resistance to an array of targeted therapy agents in various tumors. Targeting YAP signaling may improve the outcomes of targeted therapy.

(3) YAP signaling and Immunotherapy

The recent success of using immune checkpoint inhibitors for the treatment of certain human cancers represents a breakthrough in immunotherapy. Immune checkpoint receptors play a critical role in the maintenance of immune homeostasis. The classic immune checkpoint receptors include PD-1, CTLA-4, and TIGIT. The engagement of the immune checkpoint receptors can result in anergy of CD8⁺ T cells and enhance tumorigenesis and invasiveness of tumors. Immune checkpoint inhibitors remove inhibitory signals of T-cell activation, which enables tumor-reactive T cells to mount an effective antitumor response ¹⁰⁸^,¹⁰⁹. The anti-PD-1/PD-L1 agents, the most used immune checkpoint inhibitors, has shown promising outcomes in the treatment of certain cancer types, significantly extending the overall survival of patients ¹¹⁰. Monoclonal antibodies against PD-1/PD-L1 or CTLA-4 have shown promising efficacy in certain tumors ¹¹¹^-¹¹³. Emerging evidence indicates an important role for YAP signaling in modulating anti-PD-1/PD-L1 immunotherapy. PD-L1 is a direct transcriptional target of YAP signaling, knockdown of YAP inhibits expression of PD-L1 and reverses resistance to EGFR-TKI ¹¹⁴. TAZ also upregulates PD-L1 expression in pancreatic cancer, leading to immune evasion and immunotherapy resistance ¹¹⁵. Activation of YAP-mediated transcriptional hubs in the nuclei is associated with resistance of anti-PD-1 in a mouse model of lung cancer cells, and inhibition of YAP can enhance the efficacy of anti-PD-1 therapy ¹¹⁶. In addition, YAP signaling in cancer cells can facilitate recruitment of macrophages or myeloid-derived suppressor cells (MDSC) to the tumor microenvironment by regulating CXCL5, IL-6 and Csf1-3, and inhibition of YAP-mediated immune cell infiltration impairs tumor growth ¹¹⁷^,¹¹⁸. These findings indicate that targeting YAP signaling may improve the efficacy of immunotherapy.

YAP signaling and Programmed Cell Death

Apoptosis, ferroptosis and other forms of PCD are associated with cancer drug resistance ¹¹⁹^,¹²⁰. Recent studies discovered that YAP signaling plays an important role in the regulation of PCD in cancer ¹²¹. Understanding the relationship between YAP signaling and PCD can assist the development of more effective cancer therapeutic strategies.

YAP signaling and Apoptosis

Apoptosis is a major cancer cell response to most therapeutic drugs. Dysregulation of apoptosis contributes to tumorigenesis and drug resistance ¹¹⁹. YAP signaling participates in the regulation of apoptosis and inhibition of YAP signaling can promote apoptosis via multiple pathways. Inhibition of YAP signaling can promote apoptosis in multiple pathways. Knockdown of YAP and TAZ can enhance apoptosis under hypoxic condition ¹²². YAP appears to modulate cancer cell susceptibility to apoptosis triggered by an ER stress inducing agent ¹²³. Knockdown of YAP can sensitize colon cancer cells to inhibitors of the MAPK pathway, which may involve YAP-mediated expression of CDK6 ¹²⁴. YAP is implicated in playing a role in determining the switch between apoptotic and survival pathways following activation of G protein-coupled bile acid receptor (GPBAR) signaling ¹²⁵. Inhibition of YAP increases cancer cell apoptosis induced by genotoxic agents ¹²⁶. Knockdown of YAP enhances apoptosis in cancer cells treated with the Abl and Src family kinase inhibitor bosutinib, which is associated with mitochondrial fragmentation and reactive oxygen species (ROS) accumulation ¹²⁷. Indeed, knockdown of YAP increases mitochondrial fission via JNK-Drp1, which can lead to apoptosis ¹²⁸.

Activation of YAP can inhibit apoptosis by mediating the pro-apoptotic function of nuclear receptor 4A1 (NR4A1) ¹²⁹. Knockdown of YAP in cancer cells increases the levels of ER stress and apoptosis ¹⁸. Ras association domain family member 4 (RASSF4) enhances apoptosis by decreasing YAP-regulated bcl-2 expression ¹³⁰. Knockdown of YAP can induce apoptosis by reducing SIRT1- and Mfn2-mediated mitophagy ¹³¹. The YAP/TEAD4 complex can inhibit apoptosis and promote cancer progression by activating kinesin family member 4A (KIF4A) expression ¹³². Overexpression of YAP promotes proliferation and suppress apoptosis via increase of bcl-2 ¹³³. YAP knockdown sensitizes bladder cancer cells to cisplatin-induced apoptosis, which is accompanied with downregulation of surviving ¹³⁴. A recent study showed that YAP plays a vital role in evasion of apoptosis by mediating cancer cell dormancy, which involves recruitment of the EMT transcriptional factor SLUG and suppression of the expression of the pro-apoptotic protein bcl-2-modifying factor (BMF) ¹³⁵.

Further investigation of the precise mechanisms regarding the regulation of apoptosis by YAP signaling may contribute to the discovery of potential therapeutic targets.

YAP signaling and Ferroptosis

Ferroptosis is a biochemically and morphologically distinct form of PCD characterized by iron-dependent lipid peroxidation and compromise of cell membrane integrity ¹³⁶. Lipid peroxidation is a process under which oxidants such as free radicals and intracellular ROS attack lipids especially polyunsaturated fatty acids, leads to lipid peroxidation and cell death. Imbalance of iron redox ability leads to the production of oxygen free radicals and damages various cellular components, eventually induces ferroptosis. Cancer cells have developed many defense mechanisms to prevent lipid peroxidation. The most well-known is the glutathione peroxidase 4 (GPX4)-glutathione (GSH) system. GPX4 can reduce peroxidized lipids to their corresponding alcohols by binding to its cofactor GSH ¹³⁷. Ferroptosis is associated with multiple diseases, such as cancer, inflammation, heart injury and sepsis ¹³⁸^-¹⁴¹. A growing number of studies indicates that YAP signaling modulates ferroptosis by regulating expression of genes involved in keeping the balance of intracellular ROS and lipid peroxidation.

YAP can modulate iron concentration through the transcriptional regulation of transferrin receptor (TFRC) ¹⁴². Activation of YAP also confers sensitivity to ferroptosis via regulation of the arachidonate lipoxygenase 3 (ALOXE3) ¹⁴³, which promotes lipid peroxidation and ferroptosis ¹⁴⁴, or by upregulating multiple regulators of ferroptosis, particularly TRFC and acyl-CoA synthetase long chain family member 4 (ACSL4) ¹⁴⁵. TAZ mediates ferroptosis through indirectly regulating the expression of the ROS-generating nicotinamide adenine dinucleotide phosphate oxidases (NOX) through angiopoietin-like 4 (ANGPLT4)-NOX2 and epithelial membrane protein 1 (EMP1)-NOX4 axis ¹⁴⁶^,¹⁴⁷. YAP/p53 axis is required for lipid peroxidation and ferroptosis induced by cytoglobin, a heme-binding protein that mediates redox homeostasis in cells ¹⁴⁸.

However, in a separate line of studies, YAP appears to have anti-ferroptosis effect. YAP/TAZ mediate the expression of solute carrier family 7 member 11 (SLC7A11), a subunit of the cystine/glutamate transporter that is important for maintaining intracellular cysteine and glutathione storage, and thus contributes to resistance to ferroptosis ¹⁴⁹^,¹⁵⁰. Induction of ferroptosis by inhibition of the cystine/glutamate transporter system by erastin is accompanied with glutamate-induced O-GlcNAcylation and down regulation of YAP, and ectopic expression of a mutant form of YAP that cannot undergo O-GlcNAcylation reduces sensitivity to ferroptosis ¹⁵¹. Moreover, YAP can also protect cells from ferroptosis by suppressing the expression of ferritin light chain, a major protein important for storing intracellular iron ¹⁵².

In summary, YAP signaling can regulate genes involved in different aspects of lipid peroxidation. The overall effect of YAP disruption on ferroptosis may depends on the genetic background of the cell types or the metabolic environment.

YAP signaling and Autophagy

Autophagy is a mechanism by which cells adapt to physiological or pathological changes by degrading and recycling parts of the cell in a lysosome-dependent manner. Autophagy is vital in maintaining organismal homeostasis ¹⁵³^,¹⁵⁴ and dysfunction of autophagy is implicated in multiple diseases ¹⁵⁵^-¹⁵⁷. The molecular mechanism of autophagy involves several autophagy-associated proteins (ATG). Various stimuli, such as nutrient deficiencies and hypoxia, can leads to the formation of phagocytic vesicles, a step regulated by two protein complexes. One is the Vps34 complex containing Vps34, ATG6, ATG14 and Vps15. The other is the unc-51 like autophagy activating kinase (ULK1)/ATG1 complex, which is an important positive regulator of autophagosome formation ¹⁵⁸. Autophagy is involved in aspects of tumorigenesis, including cancer cell survival, invasion and immune response ¹⁵⁹^-¹⁶². Recent studies have shown complex interactions between YAP signaling and autophagic pathways ¹⁶³.

YAP signaling promotes autophagy in most tumors. YAP is required for lncRNA-ATB induced autophagy ¹⁶⁴. YAP activates autophagy by promoting ATG5 transcription, while autophagy in turn negatively regulates YAP through autophagic degradation ¹⁶⁵. Disruption of autophagy by genetic deletion of ATG7 in the hepatocytes leads to upregulation of YAP and malignant transformation in the liver, which can be reversed by concurrent deletion of YAP ¹⁶⁶. Silencing of YAP leads to impaired autophagy, which enhances cisplatin sensitivity in cancer cells ⁷⁰. Proto-oncogene SKIL could induce TAZ-dependent autophagy in NSCLC cell lines ¹⁶⁷. Cisplatin-induced autophagy can activate YAP by decreasing phosphorylation ¹⁶⁸. YAP promotes autophagy and tumor progression in glioblastoma through upregulation of high mobility group box 1 (HMGB1) ¹⁷.

Contrary to the above-mentioned studies, YAP signaling has also been shown to inhibit autophagy. YAP can suppress autophagy in sarcoma ¹⁶⁹. Autophagy induced by depletion of TAZ could inhibit migration and invasion ¹⁷⁰. Blockade of YAP induces autophagy‑related cell death and confers sensitivity of chemotherapy ¹⁹. YAP inhibits autophagy through the suppression of phosphatase and tensin homolog (PTEN) and activation of the AKT/mTOR pathway ¹⁷¹. Moreover, YAP inhibits autophagy by upregulating expression of bcl-2 ¹⁷².

In summary, YAP signaling appears to play opposing roles in regulation of autophagy, which may be dependent on the genetic background of the tumor. The mechanisms involving in the relationship between YAP signaling and autophagy needs further exploration.

YAP signaling and Pyroptosis

Pyroptosis, also known as inflammatory necrosis, is a type of PCD characterized by Gasdemin-mediated membrane rupture and release of inflammatory molecules ¹⁷³. Pyroptosis is usually initiated in response to viral and bacterial infections, accompanied by activation of the inflammasome and secretion of pro-inflammatory cytokines ¹⁷⁴. Pyroptosis facilitates inflammatory microenvironment, which promotes carcinogenesis and metastasis ¹⁷⁵. The role of pyroptosis in tumor development is complicated. In the initiation stage, pyroptosis can promote tumor development through inflammasome or the release of pro-inflammatory cytokines, such as interleukin-1β and IL-18 ¹⁷⁶^,¹⁷⁷. In later stages, the inhibition of pyroptosis may promote tumor progression ¹⁷⁸.

Pyroptosis is involved in the regulation of drug resistance in cancer. Downregulation of Gasdermin E (GSDME), a key regulator of pyroptosis, confers retinoblastoma cells resistance to chemotherapy ¹⁷⁹. Bioinformatics analysis reveals that four regulatory genes of pyroptosis are closely related to temozolomide resistance in glioma ¹⁸⁰. Caspase-1/GSDMD dependent pyroptosis is involved in cisplatin resistance of NSCLC cells ¹⁸¹. Pyroptosis induced by STAT-3β enhances cisplatin sensitivity in esophageal squamous carcinoma cells ¹⁸². In addition, pyroptosis-related gene signature has shown promise in predicting the efficacy of immunotherapy in multiple cancer types ¹⁸³. Pyroptosis improves the sensitivity of immunotherapy by remodeling tumor microenvironment ¹⁸⁴.

Existing research regarding YAP signaling on the regulation of pyroptosis is mostly focused on non-cancerous diseases like infection, inflammation and diabetes ¹⁸⁵^-¹⁸⁷ and only a few studies explored the role of YAP signaling in cancerous pyroptosis. Inactivation of YAP switch chemotherapy induced cell death from apoptosis to pyroptosis through upregulating the expression of GSDME ⁶⁹. A recent study showed that MST1 can promote ROS-induced pyroptosis, which is accompanied by inactivation of YAP via phosphorylation and results in suppression of tumor cell proliferation and invasion ¹⁸⁸.

Conclusion and Future Perspectives

In summary, YAP signaling is engaged in the regulation of multiple forms of programmed cell death, including apoptosis, ferroptosis, autophagy, and pyroptosis. Activation of YAP/TAZ contributes to resistance to a variety of tumor therapeutic modalities, such as chemotherapy, targeted therapy and immunotherapy. Verteporfin (VP), originally used for treating fundus macular degeneration, possesses potency of effectively YAP inhibition ¹⁸⁹. Several studies indicate that VP could increase sensitivity to targeted or chemotherapy drugs by inhibition of YAP ¹⁹⁰^-¹⁹⁴. Clinical trials using VP for the treatment of pancreatic cancer are underway ¹⁹⁵. As such, VP has the potential to become an anti-tumor agent of multiple tumor types in the future. More recently, a pan-TEAD inhibitor has been developed and showed activity in blocking YAP signaling and overcoming KRAS G12C inhibitor resistance ¹⁹⁶. Moreover, small molecule inhibitors of TEAD auto-palmitoylation have also been reported to exhibit potency to inhibit NF2-deficient Mesothelioma ¹⁹⁷. Similarly, K-975, a TEAD inhibitor, can inhibit the proliferation of malignant pleural mesothelioma (MPM) cell lines and provide significant survival benefit in MPM xenograft model ¹⁹⁸. In addition, several other YAP/TEAD inhibitors are currently tested in the preclinical and clinical research stages, and may provide more drug choices for YAP/TEAD based anti-tumor therapy in the future ¹⁹⁹. The advancement of our understanding in YAP or YAP-mediated signaling events in cancer drug resistance may lead to development of new therapeutic regimen for cancer.

**Hippo-YAP pathway signaling and function.** YAP signaling is negatively regulated through a cascade of phosphorylation events mediated by MST1/2 and LATS1/2, which leads to phosphorylation of YAP and subsequent proteasomal degradation or retention in the cytoplasm. Alternatively, YAP can be inactivated by binding to angiomotin, PTPN14 and zonula occludens. Signaling events triggered by GPCR and Rho can activate YAP by inducing its nuclear translocation. YAP target genes are involved in aspects of organ development, regeneration, and malignant transformation.

**YAP signaling and chemotherapy.** YAP/TAZ-mediated tumor chemoresistance by increasing survival in DNA damage and cell cycle arrest and reducing drug efflux. Anti-microtubule chemotherapeutic agents can induce G₂/M cell cycle blockade. YAP signaling regulates their resistance through pathways such as CTGF/Cyr61, ABCB1, and CDKs. YAP signaling modulates resistance to DNA damage agents through TRIM11, p53, IL-8 pathways. Gemcitabine and 5-FU affect DNA and RNA synthesis in tumor cells. YAP signaling regulates their resistance through M2 polarization.

**YAP signaling and targeted therapy.** YAP signaling drives resistance of BRAF inhibitors by regulating TESK1. YAP signaling mediates EGFR TKI resistance by via FOXM1/p62. YAP signaling mediates Trastuzumab, ALK TKI and MEK inhibitors resistance by via CCL5, EGFR/AXL and MYC/E2F, respectively.

**YAP signaling and immunotherapy.** YAP mediates immunotherapeutic resistance by regulating cytotoxic T cells through upregulation of PD-L1 expression in cancer cells. YAP-mediated transcription of CXCL5, IL-6 and Csf1-3 promotes MDSC recruitment and macrophage infiltration.

**YAP signaling in regulation of apoptosis.** YAP signaling can regulate apoptosis by modulating (1) Mitochondria-related events (e.g. bcl-2, BMF, NR4A1, SIRT1/Mfn2, survivin and JNK/Drp1); (2) ROS and ER stress responses; or (3) Mediators of the cell cycle, (e.g. CDK6 and survivin).

**YAP signaling related mechanisms in regulation of ferroptosis.** Drugs such as erastin and sorafenib directly target cystine transporter and trigger ferroptosis. Activation of YAP induce ferroptosis by upregulating the expression of ACSL4 and TRFC. Other regulators of YAP mediated ferroptosis include NOX2, NOX4, ALOXES3 and cytoglobin. Glutamate-induced O-GlcNAcylation of YAP inhibit ferroptosis. YAP signaling suppress ferroptosis by targeting SLC7A11 and ferritin light chain.

**Connection between YAP signaling and Autophagy.** lncRNA ATB and SKIL can promote autophagy via YAP signaling. YAP signaling promotes autophagy through regulation of HMGB1, ATG5. On the other hand, YAP signaling inhibits autophagy via bcl-2, and PTEN/AKT pathway. YAP signaling could regulate carcinogenesis and chemosensitivity via autophagy.

Acknowledgments

This work is supported by NIH grants 5P01CA233452.

All figures were created with BioRender.com.

Author Contributions

Wei Zhou and Qiang Wang initiated and drafted the manuscript. Adrian Lim participated in collecting related studies. Heshui Wu, Mouad Edderkaoui and Arsen Osipov participated in the design of the review. Stephen Pandol revised the manuscript. All authors have read and agreed on the published version of the manuscript.

ORCID

Wei Zhou https://orcid.org/0000-0003-2004-277X.

Abbreviations

PCD: programmed cell death
YAP: yes-associated protein
TEAD: TEA domain family
MST: mammalian Ste20-like kinases
LATS: large tumor suppressor
MOB-1: Mps one binder kinase activator-1
KIBRA: KIdney and BRAin expressed protein
WWC1: WW and C2 domain containing 1
GPCR: G-protein coupled receptors
PTPN14: protein tyrosine phosphatase non-receptor type 14
SET1A: set domain containing 1A
HCC: hepatocellular carcinoma
SCLC: small cell lung cancer
HIF: hypoxia-inducible factor
TRIM11: tripartite motif-containing protein 11
CTGF: connective tissue growth factor
ABCB1: ATP binding cassette subfamily B member 1
CYR61: cysteine-rich angiogenic inducer 61
CDK: cyclin-dependent kinase
COX-2: cyclooxygenase 2
5-FU: 5-fluorouracil
RAR: retinoic acid receptors
RXR: retinoid X receptors
ALDH1A3: aldehyde dehydrogenase 1 family member A3
OCT4: octamer-binding transcription factor 4
EGFR: epidermal growth factor receptor
HER-2: human epidermal growth factor receptor 2
VEGFR: vascular endothelial growth factor receptor
TESK1: testis associated actin remodeling Kinase 1
TKI: tyrosine kinase inhibitor
EMT: epithelial-to-mesenchymal transition
NSCLC: non-small cell lung cancer
FOXM1: forkhead box protein M1
SAC: sacsin molecular chaperone
MEK: mitogen-activated protein kinase kinase
BET: bromodomain and extra-terminal motif
PD-1: Programmed death protein 1
PD-L1: programmed cell death ligand 1
CTLA-4: cytotoxic T-lymphocyte-associated antigen 4
TIGIT: T cell immunoglobulin and ITIM domain
MDSC: myeloid-derived suppressor cells
IL-6: Interleukin 6
CSF: colony stimulating factor
CXCL5: c-x-c motif chemokine ligand 5
ER: endoplasmic reticulum
PERK: protein kinase RNA-like ER kinase
EIF2a: eukaryotic translation initiation factor 2A
MAPK: mitogen-activated protein kinase
GPBAR: G protein-coupled bile acid receptor
JNK: c-Jun n-terminal kinase
NR4A1: nuclear receptor 4A1
KIF4A: kinesin family member 4A
BMF: Bcl-2-modifying factor
GPX4: glutathione peroxidase 4
GSH: glutathione
TFRC: transferrin receptor
ACSL4: acyl-CoA synthetase long chain family member 4
NOX: nicotinamide adenine dinucleotide phosphate oxidases
SLC7A11: solute carrier family 7 member 11
ALOXE3: Arachidonate Lipoxygenase 3
SUFU: suppressor of fused homolog
ANGPLT4: angiopoietin-like 4
EMP1: epithelial membrane protein 1
ATG: autophagy-associated proteins
ULK1: unc-51 like autophagy activating kinase
TNBC: triple-negative breast cancer
ANKRD1: ankyrin repeat domain 1
ERK: extracellular signal-regulated kinase
HMGB1: high mobility group box 1
UPR: unfolded protein response
RAC1: Rac family small GTPase 1
mTOR: mechanistic target of rapamycin kinase
PTEN: phosphatase and tensin homolog
GSDME: gasdermin E
MST1: macrophage stimulating 1
VP: verteporfin

References

1.Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell. 2020;37(4):443–55. doi: 10.1016/j.ccell.2020.03.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12(1):134. doi: 10.1186/s13045-019-0818-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Yu S, Zhang C, Xie KP. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188461. doi: 10.1016/j.bbcan.2020.188461. [DOI] [PubMed] [Google Scholar]
4.Gusyatiner O, Hegi ME. Glioma epigenetics: From subclassification to novel treatment options. Semin in Cancer Biol. 2018;51:50–8. doi: 10.1016/j.semcancer.2017.11.010. [DOI] [PubMed] [Google Scholar]
5.Bao MH, Wong CC. Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. Cells. 2021;10(7):1715. doi: 10.3390/cells10071715. [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N. et al. Drug resistance in cancer: an overview. Cancers (Basel) 2014;6(3):1769–92. doi: 10.3390/cancers6031769. [DOI] [PMC free article] [PubMed] [Google Scholar]
7.Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J. et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747–61. doi: 10.1101/gad.1602907. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N. et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell. 2013;154(5):1047–59. doi: 10.1016/j.cell.2013.07.042. [DOI] [PubMed] [Google Scholar]
9.Panciera T, Azzolin L, Cordenonsi M, Piccolo S. Mechanobiology of YAP and TAZ in physiology and disease. Nat Rev Mol Cell Biol. 2017;18(12):758–70. doi: 10.1038/nrm.2017.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI. et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013;15(6):637–46. doi: 10.1038/ncb2756. [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005;122(3):421–34. doi: 10.1016/j.cell.2005.06.007. [DOI] [PubMed] [Google Scholar]
12.Zhao B, Ye X, Yu J, Li L, Li W, Li S. et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962–71. doi: 10.1101/gad.1664408. [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S. et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Bio Chem. 2009;284(20):13355–62. doi: 10.1074/jbc.M900843200. [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Zhao B, Kim J, Ye X, Lai ZC, Guan KL. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Cancer Res. 2009;69(3):1089–98. doi: 10.1158/0008-5472.CAN-08-2997. [DOI] [PubMed] [Google Scholar]
15.Li H, Wu BK, Kanchwala M, Cai J, Wang L. et al. YAP/TAZ drives cell proliferation and tumour growth via a polyamine-eIF5A hypusination-LSD1 axis. Nat Cell Biol. 2022;24(3):373–83. doi: 10.1038/s41556-022-00848-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Yuan Y, Li D, Li H, Wang L, Tian G, Dong Y. YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells. Mol Med Rep. 2016;13(1):237–42. doi: 10.3892/mmr.2015.4550. [DOI] [PubMed] [Google Scholar]
17.Zhao M, Zhang Y, Jiang Y, Wang K, Wang X, Zhou D. et al. YAP promotes autophagy and progression of gliomas via upregulating HMGB1. J Exp Clin Cancer Res. 2021;40(1):99. doi: 10.1186/s13046-021-01897-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
18.Liu H, Mei D, Xu P, Wang H, Wang Y. YAP promotes gastric cancer cell survival and migration/invasion via the ERK/endoplasmic reticulum stress pathway. Oncol Lett. 2019;18(6):6752–8. doi: 10.3892/ol.2019.11049. [DOI] [PMC free article] [PubMed] [Google Scholar]
19.Zhou Y, Wang Y, Zhou W, Chen T, Wu Q, Chutturghoon VK. et al. YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway. Cancer Cell Int. 2019;19:179. doi: 10.1186/s12935-019-0898-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
20.Marti P, Stein C, Blumer T, Abraham Y, Dill MT, Pikiolek M. et al. YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. Hepatology. 2015;62(5):1497–510. doi: 10.1002/hep.27992. [DOI] [PubMed] [Google Scholar]
21.Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G. et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene. 2015;34(6):681–90. doi: 10.1038/onc.2014.5. [DOI] [PubMed] [Google Scholar]
22.Ge L, Li DS, Chen F, Feng JD, Li B, Wang TJ. TAZ overexpression is associated with epithelial-mesenchymal transition in cisplatin-resistant gastric cancer cells. Int J Oncol. 2017;51(1):307–15. doi: 10.3892/ijo.2017.3998. [DOI] [PubMed] [Google Scholar]
23.Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B. et al. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol. 2015;17(9):1218–27. doi: 10.1038/ncb3216. [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem. 2009;284(21):14347–58. doi: 10.1074/jbc.M901568200. [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Shao D, Zhai P, Del Re DP, Sciarretta S, Yabuta N, Nojima H. et al. A functional interaction between Hippo-YAP signalling and FoxO1 mediates the oxidative stress response. Nat Commun. 2014;5:3315. doi: 10.1038/ncomms4315. [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Chen Q, Zhang N, Gray RS, Li H, Ewald AJ, Zahnow CA. et al. A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev. 2014;28(5):432–7. doi: 10.1101/gad.233676.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
27.Zhang Y, Wang Y, Zhou D, Wang K, Wang X, Wang X. et al. Radiation-induced YAP activation confers glioma radioresistance via promoting FGF2 transcription and DNA damage repair. Oncogene. 2021;40(27):4580–91. doi: 10.1038/s41388-021-01878-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol. 2003;5(10):914–20. doi: 10.1038/ncb1050. [DOI] [PubMed] [Google Scholar]
29.Chan EH, Nousiainen M, Chalamalasetty RB, Schäfer A, Nigg EA, Silljé HH. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene. 2005;24(12):2076–86. doi: 10.1038/sj.onc.1208445. [DOI] [PubMed] [Google Scholar]
30.Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell. 2013;154(6):1342–55. doi: 10.1016/j.cell.2013.08.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
31.Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N. Kibra is a regulator of the Salvador/Warts/Hippo signaling network. Dev Cell. 2010;18(2):300–8. doi: 10.1016/j.devcel.2009.12.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
32.Yu J, Zheng Y, Dong J, Klusza S, Deng WM, Pan D. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev Cell. 2010;18(2):288–99. doi: 10.1016/j.devcel.2009.12.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
33.Baumgartner R, Poernbacher I, Buser N, Hafen E, Stocker H. The WW domain protein Kibra acts upstream of Hippo in Drosophila. Dev Cell. 2010;18(2):309–16. doi: 10.1016/j.devcel.2009.12.013. [DOI] [PubMed] [Google Scholar]
34.Callus BA, Verhagen AM, Vaux DL. Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and phosphorylation. FEBS J. 2006;273(18):4264–76. doi: 10.1111/j.1742-4658.2006.05427.x. [DOI] [PubMed] [Google Scholar]
35.Praskova M, Khoklatchev A, Ortiz-Vega S, Avruch J. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem J. 2004;381(Pt 2):453–62. doi: 10.1042/BJ20040025. [DOI] [PMC free article] [PubMed] [Google Scholar]
36.Oh HJ, Lee KK, Song SJ, Jin MS, Song MS, Lee JH. et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res. 2006;66(5):2562–9. doi: 10.1158/0008-5472.CAN-05-2951. [DOI] [PubMed] [Google Scholar]
37.Dhanaraman T, Singh S, Killoran RC, Singh A, Xu X, Shifman JM. et al. RASSF effectors couple diverse RAS subfamily GTPases to the Hippo pathway. Sci Signal. 2020;13(653):eabb4778. doi: 10.1126/scisignal.abb4778. [DOI] [PubMed] [Google Scholar]
38.Hoa L, Kulaberoglu Y, Gundogdu R, Cook D, Mavis M, Gomez M. et al. The characterisation of LATS2 kinase regulation in Hippo-YAP signalling. Cell Signal. 2016;28(5):488–97. doi: 10.1016/j.cellsig.2016.02.012. [DOI] [PubMed] [Google Scholar]
39.Hergovich A, Schmitz D, Hemmings BA. The human tumour suppressor LATS1 is activated by human MOB1 at the membrane. Biochem Biophys Res Commun. 2006;345(1):50–8. doi: 10.1016/j.bbrc.2006.03.244. [DOI] [PubMed] [Google Scholar]
40.Zheng Y, Wang W, Liu B, Deng H, Uster E, Pan D. Identification of Happyhour/MAP4K as Alternative Hpo/Mst-like Kinases in the Hippo Kinase Cascade. Dev Cell. 2015;34(6):642–55. doi: 10.1016/j.devcel.2015.08.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
41.Meng Z, Moroishi T, Mottier-Pavie V, Plouffe SW, Hansen CG, Hong AW. et al. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat Commun. 2015;6:8357. doi: 10.1038/ncomms9357. [DOI] [PMC free article] [PubMed] [Google Scholar]
42.Li Q, Li S, Mana-Capelli S, Roth Flach RJ, Danai LV, Amcheslavsky A. et al. The conserved misshapen-warts-Yorkie pathway acts in enteroblasts to regulate intestinal stem cells in Drosophila. Dev Cell. 2014;31(3):291–304. doi: 10.1016/j.devcel.2014.09.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP) Genes Dev. 2010;24(1):72–85. doi: 10.1101/gad.1843810. [DOI] [PMC free article] [PubMed] [Google Scholar]
44.Li FL, Fu V, Liu G, Tang T, Konradi AW, Peng X. et al. Hippo pathway regulation by phosphatidylinositol transfer protein and phosphoinositides. Nat Chem Biol. 2022;18(10):1076–1086. doi: 10.1038/s41589-022-01061-z. [DOI] [PubMed] [Google Scholar]
45.Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M. et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 2000;19(24):6778–91. doi: 10.1093/emboj/19.24.6778. [DOI] [PMC free article] [PubMed] [Google Scholar]
46.Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev. 2001;15(10):1229–41. doi: 10.1101/gad.888601. [DOI] [PMC free article] [PubMed] [Google Scholar]
47.Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D. et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem. 2010;285(48):37159–69. doi: 10.1074/jbc.M110.152942. [DOI] [PMC free article] [PubMed] [Google Scholar]
48.Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A. et al. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene. 2013;32(17):2220–9. doi: 10.1038/onc.2012.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
49.Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J. et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev. 2010;24(11):1106–18. doi: 10.1101/gad.1903310. [DOI] [PMC free article] [PubMed] [Google Scholar]
50.Liu X, Yang N, Figel SA, Wilson KE, Morrison CD, Gelman IH. et al. PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene. 2013;32(10):1266–73. doi: 10.1038/onc.2012.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
51.Oka T, Remue E, Meerschaert K, Vanloo B, Boucherie C, Gfeller D. et al. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. Biochem J. 2010;432(3):461–72. doi: 10.1042/BJ20100870. [DOI] [PubMed] [Google Scholar]
52.Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M. et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014;25(6):831–45. doi: 10.1016/j.ccr.2014.04.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
53.Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S. et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 2014;16(4):357–66. doi: 10.1038/ncb2936. [DOI] [PubMed] [Google Scholar]
54.Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH. et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150(4):780–91. doi: 10.1016/j.cell.2012.06.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
55.Park HW, Kim YC, Yu B, Moroishi T, Mo JS, Plouffe SW. et al. Alternative Wnt Signaling Activates YAP/TAZ. Cell. 2015;162(4):780–94. doi: 10.1016/j.cell.2015.07.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
56.Li C, Peng Z, Wang Y, Lam G, Nissen N, Tang J. et al. Epithelial cell transforming 2 is regulated by Yes-associated protein 1 and mediates pancreatic cancer progression and metastasis. Am J Physiol Gastrointest Liver Physiol. 2021;320(3):G380–G395. doi: 10.1152/ajpgi.00185.2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
57.Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX. et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015;519(7541):57–62. doi: 10.1038/nature14228. [DOI] [PMC free article] [PubMed] [Google Scholar]
58.Levy D, Adamovich Y, Reuven N, Shaul Y. Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell. 2008;29(3):350–61. doi: 10.1016/j.molcel.2007.12.022. [DOI] [PubMed] [Google Scholar]
59.Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ. et al. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151(7):1457–73. doi: 10.1016/j.cell.2012.11.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
60.Fang L, Teng H, Wang Y, Liao G, Weng L, Li Y. et al. SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis. Cancer Cell. 2018;34(1):103–18. doi: 10.1016/j.ccell.2018.06.002. [DOI] [PubMed] [Google Scholar]
61.Peng C, Zhu Y, Zhang W, Liao Q, Chen Y, Zhao X. et al. Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation. Mol Cell. 2017;68(3):591–604. doi: 10.1016/j.molcel.2017.10.010. [DOI] [PubMed] [Google Scholar]
62.Kim E, Kang JG, Kang MJ, Park JH, Kim YJ, Kweon TH. et al. O-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity. Proc Natl Acad Sci U S A. 2020;117(25):14259–69. doi: 10.1073/pnas.1913469117. [DOI] [PMC free article] [PubMed] [Google Scholar]
63.Yang S, Xu W, Liu C, Jin J, Li X, Jiang Y. et al. LATS1 K751 acetylation blocks activation of Hippo signalling and switches LATS1 from a tumor suppressor to an oncoprotein. Sci China Life Sci. 2022;65(1):129–41. doi: 10.1007/s11427-020-1914-3. [DOI] [PubMed] [Google Scholar]
64.Tang J, Tian Z, Liao X, Wu G. SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer. Int J Biol Sci. 2021;17(2):417–29. doi: 10.7150/ijbs.54194. [DOI] [PMC free article] [PubMed] [Google Scholar]
65.Huo X, Zhang QI, Liu AM, Tang C, Gong Y, Bian J. et al. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma. Oncol Rep. 2013;29(2):840–6. doi: 10.3892/or.2012.2176. [DOI] [PubMed] [Google Scholar]
66.Wang DY, Wu YN, Huang JQ, Wang W, Xu M, Jia JP. et al. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance. Chin J Cancer. 2016;35:47. doi: 10.1186/s40880-016-0109-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
67.Tao Y, Shan L, Xu X, Jiang H, Chen R, Qian Z. et al. Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma. J Cancer. 2018;9(21):3962–70. doi: 10.7150/jca.25909. [DOI] [PMC free article] [PubMed] [Google Scholar]
68.Dai XY, Zhuang LH, Wang DD, Zhou TY, Chang LL, Gai RH. et al. Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells. Oncotarget. 2016;7(6):6933–47. doi: 10.18632/oncotarget.6903. [DOI] [PMC free article] [PubMed] [Google Scholar]
69.Wu Q, Guo J, Liu Y, Zheng Q, Li X, Wu C. et al. YAP drives fate conversion and chemoresistance of small cell lung cancer. Sci Adv. 2021;7(40):eabg1850. doi: 10.1126/sciadv.abg1850. [DOI] [PMC free article] [PubMed] [Google Scholar]
70.Xiao L, Shi XY, Zhang Y, Zhu Y, Zhu L, Tian W. et al. YAP induces cisplatin resistance through activation of autophagy in human ovarian carcinoma cells. Onco Targets Ther. 2016;9:1105–14. doi: 10.2147/OTT.S102837. [DOI] [PMC free article] [PubMed] [Google Scholar]
71.Bi L, Ma F, Tian R, Zhou Y, Lan W, Song Q. et al. AJUBA increases the cisplatin resistance through hippo pathway in cervical cancer. Gene. 2018;644:148–54. doi: 10.1016/j.gene.2017.11.017. [DOI] [PubMed] [Google Scholar]
72.Xu W, Wei Y, Li Y, Yin Y, Yuan W, Yang Y. et al. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma. Oncol Rep. 2017;38(3):1815–21. doi: 10.3892/or.2017.5847. [DOI] [PubMed] [Google Scholar]
73.Li C, Wang Q, Luo Y, Xiang J. TAZ Regulates the Cisplatin Resistance of Epithelial Ovarian Cancer Cells via the ANGPTL4/SOX2 Axis. Anal Cell Pathol (Amst) 2022;2022:5632164. doi: 10.1155/2022/5632164. [DOI] [PMC free article] [PubMed] [Google Scholar]
74.Jiang Z, Chen X, Chen K, Sun L, Gao L, Zhou C. et al. YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine. Nutrients. 2016;8(10):546. doi: 10.3390/nu8100546. [DOI] [PMC free article] [PubMed] [Google Scholar]
75.He Z, Chen D, Wu J, Sui C, Deng X, Zhang P. et al. Yes associated protein 1 promotes resistance to 5-fluorouracil in gastric cancer by regulating GLUT3-dependent glycometabolism reprogramming of tumor-associated macrophages. Arch Biochem Biophys. 2021;702:108838. doi: 10.1016/j.abb.2021.108838. [DOI] [PubMed] [Google Scholar]
76.Gujral TS, Kirschner MW. Hippo pathway mediates resistance to cytotoxic drugs. Proc Natl Acad Sci U S A. 2017;114(18):E3729–38. doi: 10.1073/pnas.1703096114. [DOI] [PMC free article] [PubMed] [Google Scholar]
77.Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming. Drug Resist Updat. 2021;54:100742. doi: 10.1016/j.drup.2020.100742. [DOI] [PubMed] [Google Scholar]
78.Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB. et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 2011;30(25):2810–22. doi: 10.1038/onc.2011.8. [DOI] [PubMed] [Google Scholar]
79.Li W, Cao Y, Xu J, Wang Y, Li W, Wang Q. et al. YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer. J Expe Clin Cancer Res. 2017;36(1):144. doi: 10.1186/s13046-017-0612-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
80.Lai D, Ho KC, Hao Y, Yang X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 2011;71(7):2728–38. doi: 10.1158/0008-5472.CAN-10-2711. [DOI] [PubMed] [Google Scholar]
81.Ma J, Fan Z, Tang Q, Xia H, Zhang T, Bi F. Aspirin attenuates YAP and β-catenin expression by promoting β-TrCP to overcome docetaxel and vinorelbine resistance in triple-negative breast cancer. Cell Death Dis. 2020;11(7):530. doi: 10.1038/s41419-020-2719-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
82.Xia Y, Zhang YL, Yu C, Chang T, Fan HY. YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells. PloS one. 2014;9(11):e109575. doi: 10.1371/journal.pone.0109575. [DOI] [PMC free article] [PubMed] [Google Scholar]
83.Weiler SME, Pinna F, Wolf T, Lutz T, Geldiyev A, Sticht C. et al. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer. Gastroenterology. 2017;152(8):2037–51.e22. doi: 10.1053/j.gastro.2017.02.018. [DOI] [PubMed] [Google Scholar]
84.Pattschull G, Walz S, Gründl M, Schwab M, Rühl E, Baluapuri A. et al. The Myb-MuvB Complex Is Required for YAP-Dependent Transcription of Mitotic Genes. Cell Rep. 2019;27(12):3533–46.e7. doi: 10.1016/j.celrep.2019.05.071. [DOI] [PubMed] [Google Scholar]
85.Yang S, Zhang L, Liu M, Chong R, Ding SJ, Chen Y. et al. CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation. Cancer Res. 2013;73(22):6722–33. doi: 10.1158/0008-5472.CAN-13-2049. [DOI] [PMC free article] [PubMed] [Google Scholar]
86.Pellosi DS, Paula LB, de Melo MT, Tedesco AC. Targeted and Synergic Glioblastoma Treatment: Multifunctional Nanoparticles Delivering Verteporfin as Adjuvant Therapy for Temozolomide Chemotherapy. Mol Pharm. 2019;16(3):1009–24. doi: 10.1021/acs.molpharmaceut.8b01001. [DOI] [PubMed] [Google Scholar]
87.El-Sahli S, Hua K, Sulaiman A, Chambers J, Li L, Farah E. et al. A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature. Cell Death Dis. 2021;12(1):8. doi: 10.1038/s41419-020-03308-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
88.Tsimberidou AM. Targeted therapy in cancer. Cancer Chemother Pharmacol. 2015;76(6):1113–32. doi: 10.1007/s00280-015-2861-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
89.Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37(24):3183–99. doi: 10.1038/s41388-018-0171-x. [DOI] [PubMed] [Google Scholar]
90.Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508(7494):118–22. doi: 10.1038/nature13121. [DOI] [PubMed] [Google Scholar]
91.Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84–7. doi: 10.1126/science.1247005. [DOI] [PMC free article] [PubMed] [Google Scholar]
92.Kim MH, Kim J, Hong H, Lee SH, Lee JK, Jung E. et al. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. EMBO J. 2016;35(5):462–78. doi: 10.15252/embj.201592081. [DOI] [PMC free article] [PubMed] [Google Scholar]
93.Kim MH, Kim CG, Kim SK, Shin SJ, Choe EA, Park SH. et al. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. Cancer Immunol Res. 2018;6(3):255–66. doi: 10.1158/2326-6066.CIR-17-0320. [DOI] [PubMed] [Google Scholar]
94.Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014;24(1):26–34. doi: 10.1016/j.tcb.2013.11.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
95.Wang H, Lu B, Castillo J, Zhang Y, Yang Z, McAllister G. et al. Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling. J Biol Chem. 2016;291(29):15256–66. doi: 10.1074/jbc.M116.722967. [DOI] [PMC free article] [PubMed] [Google Scholar]
96.Lee JE, Park HS, Lee D, Yoo G, Kim T, Jeon H. et al. Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. Biochem Biophys Res Comm. 2016;474(1):154–60. doi: 10.1016/j.bbrc.2016.04.089. [DOI] [PubMed] [Google Scholar]
97.Lee TF, Tseng YC, Nguyen PA, Li YC, Ho CC, Wu CW. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas. Sci Rep. 2018;8(1):271. doi: 10.1038/s41598-017-18527-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
98.Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J. et al. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci Transl Med. 2020;12(559):eaaz4589. doi: 10.1126/scitranslmed.aaz4589. [DOI] [PMC free article] [PubMed] [Google Scholar]
99.Ghiso E, Migliore C, Ciciriello V, Morando E, Petrelli A, Corso S. et al. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC. Neoplasia. 2017;19(12):1012–21. doi: 10.1016/j.neo.2017.10.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
100.Park HS, Lee DH, Kang DH, Yeo MK, Bae G, Lee D. et al. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma. Cancer Med. 2021;10(4):1405–17. doi: 10.1002/cam4.3734. [DOI] [PMC free article] [PubMed] [Google Scholar]
101.Shi J, Li F, Yao X, Mou T, Xu Z, Han Z. et al. The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition. Oncogene. 2018;37(22):3022–38. doi: 10.1038/s41388-018-0204-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
102.Cheng H, Zhang Z, Rodriguez-Barrueco R, Borczuk A, Liu H, Yu J. et al. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells. Oncotarget. 2016;7(20):28976–88. doi: 10.18632/oncotarget.6721. [DOI] [PMC free article] [PubMed] [Google Scholar]
103.González-Alonso P, Zazo S, Martín-Aparicio E, Luque M, Chamizo C, Sanz-Álvarez M. et al. The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer. Cancers (Basel) 2020;12(5):1108. doi: 10.3390/cancers12051108. [DOI] [PMC free article] [PubMed] [Google Scholar]
104.Coggins GE, Farrel A, Rathi KS, Hayes CM, Scolaro L, Rokita JL. et al. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling. Cancer Res. 2019;79(24):6204–14. doi: 10.1158/0008-5472.CAN-19-1415. [DOI] [PMC free article] [PubMed] [Google Scholar]
105.Rao G, Kim IK, Conforti F, Liu J, Zhang YW, Giaccone G. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity. Eur J Cancer. 2018;99:37–48. doi: 10.1016/j.ejca.2018.05.013. [DOI] [PubMed] [Google Scholar]
106.Yun MR, Choi HM, Lee YW, Joo HS, Park CW, Choi JW. et al. Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer. EMBO Mol Med. 2019;11(12):e10581. doi: 10.15252/emmm.201910581. [DOI] [PMC free article] [PubMed] [Google Scholar]
107.Gobbi G, Donati B, Do Valle IF, Reggiani F, Torricelli F, Remondini D. et al. The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. Oncogene. 2019;38(42):6801–17. doi: 10.1038/s41388-019-0924-1. [DOI] [PubMed] [Google Scholar]
108.Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8(9):1069–86. doi: 10.1158/2159-8290.CD-18-0367. [DOI] [PubMed] [Google Scholar]
109.Liu X, Yang L, Tan X. PD-1/PD-L1 pathway: A double-edged sword in periodontitis. Biomed Pharmacother. 2023;159:114215. doi: 10.1016/j.biopha.2023.114215. [DOI] [PubMed] [Google Scholar]
110.Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335–7. doi: 10.1172/JCI83871. [DOI] [PMC free article] [PubMed] [Google Scholar]
111.Rodríguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E. et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881–95. doi: 10.1016/j.annonc.2021.04.008. [DOI] [PubMed] [Google Scholar]
112.Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108–21. doi: 10.1056/NEJMoa1809615. [DOI] [PubMed] [Google Scholar]
113.Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E. et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020–31. doi: 10.1056/NEJMoa1910231. [DOI] [PubMed] [Google Scholar]
114.Lee BS, Park DI, Lee DH, Lee JE, Yeo MK, Park YH. et al. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. Biochem Biophys Res Commun. 2017;491(2):493–9. doi: 10.1016/j.bbrc.2017.07.007. [DOI] [PubMed] [Google Scholar]
115.Janse van Rensburg HJ, Azad T, Ling M, Hao Y, Snetsinger B, Khanal P. et al. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1. Cancer Res. 2018;78(6):1457–70. doi: 10.1158/0008-5472.CAN-17-3139. [DOI] [PubMed] [Google Scholar]
116.Ni X, Tao J, Barbi J, Chen Q, Park BV, Li Z. et al. YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity. Cancer Discov. 2018;8(8):1026–43. doi: 10.1158/2159-8290.CD-17-1124. [DOI] [PMC free article] [PubMed] [Google Scholar]
117.Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S. et al. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov. 2016;6(1):80–95. doi: 10.1158/2159-8290.CD-15-0224. [DOI] [PMC free article] [PubMed] [Google Scholar]
118.Murakami S, Shahbazian D, Surana R, Zhang W, Chen H, Graham GT. et al. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene. 2017;36(9):1232–44. doi: 10.1038/onc.2016.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
119.Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395–417. doi: 10.1038/s41571-020-0341-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
120.Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21(1):47. doi: 10.1186/s12943-022-01530-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
121.Cheng Y, Mao M, Lu Y. The biology of YAP in programmed cell death. Biomark Res. 2022;10(1):34. doi: 10.1186/s40364-022-00365-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
122.Yan B, Li T, Shen L, Zhou Z, Liu X, Wang X. et al. Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition. Biochem Biophys Res Commun. 2019;515(2):275–81. doi: 10.1016/j.bbrc.2019.05.143. [DOI] [PubMed] [Google Scholar]
123.Wang J, Chen M, Wang M, Zhao W, Zhang C, Liu X. et al. The novel ER stress inducer Sec C triggers apoptosis by sulfating ER cysteine residues and degrading YAP via ER stress in pancreatic cancer cells. Acta Pharm Sinica B. 2022;12(1):210–27. doi: 10.1016/j.apsb.2021.07.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
124.Su M, Zhan L, Zhang Y, Zhang J. Yes-activated protein promotes primary resistance of BRAF V600E mutant metastatic colorectal cancer cells to mitogen-activated protein kinase pathway inhibitors. J Gastrointest Oncol. 2021;12(3):953–63. doi: 10.21037/jgo-21-258. [DOI] [PMC free article] [PubMed] [Google Scholar]
125.Ma L, Yang F, Wu X, Mao C, Guo L, Miao T. et al. Structural basis and molecular mechanism of biased GPBAR signaling in regulating NSCLC cell growth via YAP activity. Proc Natl Acad Sci U S A. 2022;119(29):e2117054119. doi: 10.1073/pnas.2117054119. [DOI] [PMC free article] [PubMed] [Google Scholar]
126.Song Y, Sun Y, Lei Y, Yang K, Tang R. YAP1 promotes multidrug resistance of small cell lung cancer by CD74-related signaling pathways. Cancer Med. 2020;9(1):259–68. doi: 10.1002/cam4.2668. [DOI] [PMC free article] [PubMed] [Google Scholar]
127.Patrick S, Gowda P, Lathoria K, Suri V, Sen E. YAP1-mediated regulation of mitochondrial dynamics in IDH1 mutant gliomas. J Cell Sci. 2021;134(22):jcs259188. doi: 10.1242/jcs.259188. [DOI] [PubMed] [Google Scholar]
128.Li H, He F, Zhao X, Zhang Y, Chu X, Hua C, YAP Inhibits the Apoptosis and Migration of Human Rectal Cancer Cells via Suppression of JNK-Drp1-Mitochondrial Fission-HtrA2/Omi Pathways. Cell Physiol Biochem. 2017. 44(5) 2073-89. [DOI] [PubMed]
129.He L, Yuan L, Yu W, Sun Y, Jiang D, Wang X. et al. A Regulation Loop between YAP and NR4A1 Balances Cell Proliferation and Apoptosis. Cell Rep. 2020;33(3):108284. doi: 10.1016/j.celrep.2020.108284. [DOI] [PubMed] [Google Scholar]
130.Han Y, Zhang X, Guan M, Huo C, Yu C, Hu B. et al. RASSF4 inhibits cell proliferation and increases drug sensitivity in colorectal cancer through YAP/Bcl-2 pathway. J Cell Mol Med. 2022;26(12):3538–47. doi: 10.1111/jcmm.17395. [DOI] [PMC free article] [PubMed] [Google Scholar]
131.Yan H, Qiu C, Sun W, Gu M, Xiao F, Zou J. et al. Yap regulates gastric cancer survival and migration via SIRT1/Mfn2/mitophagy. Oncol Rep. 2018;39(4):1671–81. doi: 10.3892/or.2018.6252. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
132.Li Y, Zhu X, Yang M, Wang Y, Li J, Fang J. et al. YAP/TEAD4-induced KIF4A contributes to the progression and worse prognosis of esophageal squamous cell carcinoma. Mol Carcinog. 2021;60(7):440–54. doi: 10.1002/mc.23303. [DOI] [PubMed] [Google Scholar]
133.Zhao Q, Jia X, Zhang Y, Dong Y, Lei Y, Tan X. et al. Tetrandrine induces apoptosis in human neuroblastoma through regulating the Hippo/YAP signaling pathway. Biochem Biophys Res Commun. 2019;513(4):846–51. doi: 10.1016/j.bbrc.2019.04.075. [DOI] [PubMed] [Google Scholar]
134.Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L. et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. 2016;35(12):1541–53. doi: 10.1038/onc.2015.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
135.Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A. et al. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 2020;37(1):104–22.e12. doi: 10.1016/j.ccell.2019.12.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
136.Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72. doi: 10.1016/j.cell.2012.03.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
137.Vucetic M, Daher B, Cassim S, Meira W, Pouyssegur J. Together we stand, apart we fall: how cell-to-cell contact/interplay provides resistance to ferroptosis. Cell Death Dis. 2020;11(9):789. doi: 10.1038/s41419-020-02994-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
138.Battaglia AM, Chirillo R, Aversa I, Sacco A, Costanzo F, Biamonte F. Ferroptosis and Cancer: Mitochondria Meet the "Iron Maiden" Cell Death. Cells. 2020;9(6):1505. doi: 10.3390/cells9061505. [DOI] [PMC free article] [PubMed] [Google Scholar]
139.Chen X, Kang R, Kroemer G, Tang D. Ferroptosis in infection, inflammation, and immunity. J Exp Med. 2021;218(6):e20210518. doi: 10.1084/jem.20210518. [DOI] [PMC free article] [PubMed] [Google Scholar]
140.Wu X, Li Y, Zhang S, Zhou X. Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics. 2021;11(7):3052–9. doi: 10.7150/thno.54113. [DOI] [PMC free article] [PubMed] [Google Scholar]
141.Xl L, Gy Z, R G, N C. Ferroptosis in sepsis: The mechanism, the role and the therapeutic potential. Front Immunol. 2022;13:956361. doi: 10.3389/fimmu.2022.956361. [DOI] [PMC free article] [PubMed] [Google Scholar]
142.Zhu G, Murshed A, Li H, Ma J, Zhen N, Ding M. et al. O-GlcNAcylation enhances sensitivity to RSL3-induced ferroptosis via the YAP/TFRC pathway in liver cancer. Cell Death Discov. 2021;7(1):83. doi: 10.1038/s41420-021-00468-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
143.Qin Y, Pei Z, Feng Z, Lin P, Wang S, Li Y. et al. Oncogenic Activation of YAP Signaling Sensitizes Ferroptosis of Hepatocellular Carcinoma via ALOXE3-Mediated Lipid Peroxidation Accumulation. Front Cell Dev Biol. 2021;9:751593. doi: 10.3389/fcell.2021.751593. [DOI] [PMC free article] [PubMed] [Google Scholar]
144.Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A. 2016;113(34):E4966–75. doi: 10.1073/pnas.1603244113. [DOI] [PMC free article] [PubMed] [Google Scholar]
145.Wu J, Minikes AM, Gao M, Bian H, Li Y, Stockwell BR. et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature. 2019;572(7769):402–6. doi: 10.1038/s41586-019-1426-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
146.Yang WH, Ding CC, Sun T, Rupprecht G, Lin CC, Hsu D. et al. The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma. Cell Rep. 2019;28(10):2501–8.e4. doi: 10.1016/j.celrep.2019.07.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
147.Yang WH, Huang Z, Wu J, Ding CC, Murphy SK, Chi JT. A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer. Mol Cancer Res. 2020;18(1):79–90. doi: 10.1158/1541-7786.MCR-19-0691. [DOI] [PMC free article] [PubMed] [Google Scholar]
148.Ye S, Xu M, Zhu T, Chen J, Shi S, Jiang H. et al. Cytoglobin promotes sensitivity to ferroptosis by regulating p53-YAP1 axis in colon cancer cells. J Cell Mol Med. 2021;25(7):3300–11. doi: 10.1111/jcmm.16400. [DOI] [PMC free article] [PubMed] [Google Scholar]
149.Gao R, Kalathur RKR, Coto-Llerena M, Ercan C, Buechel D, Shuang S. et al. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med. 2021;13(12):e14351. doi: 10.15252/emmm.202114351. [DOI] [PMC free article] [PubMed] [Google Scholar]
150.Zhang Y, Li Y, Qiu Q, Chen Z, Du Y, Liu X. MITD1 Deficiency Suppresses Clear Cell Renal Cell Carcinoma Growth and Migration by Inducing Ferroptosis through the TAZ/SLC7A11 Pathway. Oxid Med Cell longev. 2022;2022:7560569. doi: 10.1155/2022/7560569. [DOI] [PMC free article] [PubMed] [Google Scholar]
151.Zhang X, Yu K, Ma L, Qian Z, Tian X, Miao Y. et al. Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma. Theranostics. 2021;11(12):5650–74. doi: 10.7150/thno.55482. [DOI] [PMC free article] [PubMed] [Google Scholar]
152.Wang Y, Qiu S, Wang H, Cui J, Tian X, Miao Y. et al. Transcriptional Repression of Ferritin Light Chain Increases Ferroptosis Sensitivity in Lung Adenocarcinoma. Front Cell Dev Biol. 2021;9:719187. doi: 10.3389/fcell.2021.719187. [DOI] [PMC free article] [PubMed] [Google Scholar]
153.Mizushima N, Levine B. Autophagy in Human Diseases. New Engl J Med. 2020;383(16):1564–76. doi: 10.1056/NEJMra2022774. [DOI] [PubMed] [Google Scholar]
154.Klionsky DJ, Petroni G, Amaravadi RK, Baehrecke EH, Ballabio A, Boya P. et al. Autophagy in major human diseases. EMBO J. 2021;40(19):e108863. doi: 10.15252/embj.2021108863. [DOI] [PMC free article] [PubMed] [Google Scholar]
155.Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528–42. doi: 10.1038/nrc.2017.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
156.White E, Mehnert JM, Chan CS. Autophagy, Metabolism, and Cancer. Clin Cancer Res. 2015;21(22):5037–46. doi: 10.1158/1078-0432.CCR-15-0490. [DOI] [PMC free article] [PubMed] [Google Scholar]
157.White E. The role for autophagy in cancer. J Clin Invest. 2015;125(1):42–6. doi: 10.1172/JCI73941. [DOI] [PMC free article] [PubMed] [Google Scholar]
158.Majeed ST, Majeed R, Andrabi KI. Expanding the view of the molecular mechanisms of autophagy pathway. J Cell Physiol. 2022;237(8):3257–77. doi: 10.1002/jcp.30819. [DOI] [PubMed] [Google Scholar]
159.Marsh T, Debnath J. Autophagy suppresses breast cancer metastasis by degrading NBR1. Autophagy. 2020;16(6):1164–5. doi: 10.1080/15548627.2020.1753001. [DOI] [PMC free article] [PubMed] [Google Scholar]
160.Kudo Y, Sugimoto M, Arias E, Kasashima H, Cordes T, Linares JF. et al. PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression. Cancer Cell. 2020;38(2):247–62.e11. doi: 10.1016/j.ccell.2020.05.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
161.Miao CC, Hwang W, Chu LY, Yang LH, Ha CT, Chen PY. et al. LC3A-mediated autophagy regulates lung cancer cell plasticity. Autophagy. 2022;18(4):921–34. doi: 10.1080/15548627.2021.1964224. [DOI] [PMC free article] [PubMed] [Google Scholar]
162.Yamamoto K, Venida A, Yano J, Biancur DE, Kakiuchi M, Gupta S. et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581(7806):100–5. doi: 10.1038/s41586-020-2229-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
163.Wang D, He J, Huang B, Liu S, Zhu H, Xu T. Emerging role of the Hippo pathway in autophagy. Cell Death Dis. 2020;11(10):880. doi: 10.1038/s41419-020-03069-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
164.Wang CZ, Yan GX, Dong DS, Xin H, Liu ZY. LncRNA-ATB promotes autophagy by activating Yes-associated protein and inducing autophagy-related protein 5 expression in hepatocellular carcinoma. World J Gastroenterol. 2019;25(35):5310–22. doi: 10.3748/wjg.v25.i35.5310. [DOI] [PMC free article] [PubMed] [Google Scholar]
165.Sun T, Peng H, Mao W, Ma L, Liu H, Mai J. et al. Autophagy-mediated negative feedback attenuates the oncogenic activity of YAP in pancreatic cancer. Int J Biol Sci. 2021;17(13):3634–45. doi: 10.7150/ijbs.61795. [DOI] [PMC free article] [PubMed] [Google Scholar]
166.Lee YA, Noon LA, Akat KM, Ybanez MD, Lee TF, Berres ML. et al. Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nature Commun. 2018;9(1):4962. doi: 10.1038/s41467-018-07338-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
167.Ma F, Ding MG, Lei YY, Luo LH, Jiang S, Feng YH. et al. SKIL facilitates tumorigenesis and immune escape of NSCLC via upregulating TAZ/autophagy axis. Cell Death Dis. 2020;11(12):1028. doi: 10.1038/s41419-020-03200-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
168.Jiang Y, Ji F, Liu Y, He M, Zhang Z, Yang J. et al. Cisplatin-induced autophagy protects breast cancer cells from apoptosis by regulating yes-associated protein. Oncol Rep. 2017;38(6):3668–76. doi: 10.3892/or.2017.6035. [DOI] [PubMed] [Google Scholar]
169.Rivera-Reyes A, Ye S, G EM, Egolf S, G EC, Chor S. et al. YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma. Cell Death Dis. 2018;9(11):1108. doi: 10.1038/s41419-018-1142-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
170.Zhou W, Weng J, Wu K, Xu X, Wang H, Zhang J. et al. Silencing of TAZ inhibits the motility of hepatocellular carcinoma cells through autophagy induction. Cancer Manag Res. 2019;11:8743–53. doi: 10.2147/CMAR.S215466. [DOI] [PMC free article] [PubMed] [Google Scholar]
171.Xu W, Zhang M, Li Y, Wang Y, Wang K, Chen Q. et al. YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas. Cancer Cell Int. 2021;21(1):30. doi: 10.1186/s12935-020-01688-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
172.Jin L, Chen Y, Cheng D, He Z, Shi X, Du B. et al. YAP inhibits autophagy and promotes progression of colorectal cancer via upregulating Bcl-2 expression. Cell Death Dis. 2021;12(5):457. doi: 10.1038/s41419-021-03722-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
173.Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity. Mol Cell. 2021;81(22):4579–90. doi: 10.1016/j.molcel.2021.09.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
174.Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660–5. doi: 10.1038/nature15514. [DOI] [PubMed] [Google Scholar]
175.Jia Y, Wang X, Deng Y, Li S, Xu X, Qin Y. et al. Pyroptosis Provides New Strategies for the Treatment of Cancer. J Cancer. 2023;14(1):140–51. doi: 10.7150/jca.77965. [DOI] [PMC free article] [PubMed] [Google Scholar]
176.Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C. et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A. 2010;107(50):21635–40. doi: 10.1073/pnas.1016814108. [DOI] [PMC free article] [PubMed] [Google Scholar]
177.Van Gorp H, Lamkanfi M. The emerging roles of inflammasome-dependent cytokines in cancer development. EMBO Rep. 2019;20(6):e47575. doi: 10.15252/embr.201847575. [DOI] [PMC free article] [PubMed] [Google Scholar]
178.Wang WJ, Chen D, Jiang MZ, Xu B, Li XW, Chu Y. et al. Downregulation of gasdermin D promotes gastric cancer proliferation by regulating cell cycle-related proteins. J Dig Dis. 2018;19(2):74–83. doi: 10.1111/1751-2980.12576. [DOI] [PubMed] [Google Scholar]
179.Li F, Xia Q, Ren L, Nie Y, Ren H, Guo X. et al. GSDME Increases Chemotherapeutic Drug Sensitivity by Inducing Pyroptosis in Retinoblastoma Cells. Oxid Med Cell Longev. 2022;2022:2371807. doi: 10.1155/2022/2371807. [DOI] [PMC free article] [PubMed] [Google Scholar]
180.Liang L, Yan B, Liu Y, Jiang S, He H, Huang J. et al. FOXP3 Contributes to TMZ Resistance, Prognosis, and Immune Infiltration in GBM from a Novel Pyroptosis-Associated Risk Signature. Dis Markers. 2022;2022:4534080. doi: 10.1155/2022/4534080. [DOI] [PMC free article] [PubMed] [Google Scholar]
181.Cheng Z, Li Z, Gu L, Li L, Gao Q, Zhang X. et al. Ophiopogonin B alleviates cisplatin resistance of lung cancer cells by inducing Caspase-1/GSDMD dependent pyroptosis. J Cancer. 2022;13(2):715–27. doi: 10.7150/jca.66432. [DOI] [PMC free article] [PubMed] [Google Scholar]
182.Zheng ZY, Yang PL, Li RY, Liu LX, Xu XE, Liao LD. et al. STAT3β disrupted mitochondrial electron transport chain enhances chemosensitivity by inducing pyroptosis in esophageal squamous cell carcinoma. Cancer Lett. 2021;522:171–83. doi: 10.1016/j.canlet.2021.09.035. [DOI] [PubMed] [Google Scholar]
183.Li S, Chen P, Cheng B, Liu Y, Zhang X, Xu Q. et al. Pyroptosis predicts immunotherapy outcomes across multiple cancer types. Clin Immunol. 2022;245:109163. doi: 10.1016/j.clim.2022.109163. [DOI] [PubMed] [Google Scholar]
184.Wang M, Wu M, Liu X, Shao S, Huang J, Liu B. et al. Pyroptosis Remodeling Tumor Microenvironment to Enhance Pancreatic Cancer Immunotherapy Driven by Membrane Anchoring Photosensitizer. Adv Sci (Weinh) 2022;9(29):e2202914. doi: 10.1002/advs.202202914. [DOI] [PMC free article] [PubMed] [Google Scholar]
185.Zhang T, Lu L, Li M, Zhang D, Yu P, Zhang X. et al. Exosome from BMMSC attenuates cardiopulmonary bypass-induced acute lung injury via YAP/β-catenin pathway: down-regulation of pyroptosis. Stem Cells. 2022;40(12):1122–1133. doi: 10.1093/stmcls/sxac063. [DOI] [PubMed] [Google Scholar]
186.Hong L, Zha Y, Wang C, Qiao S, An J. Folic Acid Alleviates High Glucose and Fat-Induced Pyroptosis via Inhibition of the Hippo Signal Pathway on H9C2 Cells. Front Mol Biosci. 2021;8:698698. doi: 10.3389/fmolb.2021.698698. [DOI] [PMC free article] [PubMed] [Google Scholar]
187.García-Gil A, Galán-Enríquez CS, Pérez-López A, Nava P, Alpuche-Aranda C, Ortiz-Navarrete V. SopB activates the Akt-YAP pathway to promote Salmonella survival within B cells. Virulence. 2018;9(1):1390–402. doi: 10.1080/21505594.2018.1509664. [DOI] [PMC free article] [PubMed] [Google Scholar]
188.Cui J, Zhou Z, Yang H, Jiao F, Li N, Gao Y. et al. MST1 Suppresses Pancreatic Cancer Progression via ROS-Induced Pyroptosis. Mol Cancer Res. 2019;17(6):1316–25. doi: 10.1158/1541-7786.MCR-18-0910. [DOI] [PubMed] [Google Scholar]
189.Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA. et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26(12):1300–5. doi: 10.1101/gad.192856.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
190.Zhao X, Wang X, Fang L, Lan C, Zheng X, Wang Y. et al. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. Cancer Lett. 2017;402:61–70. doi: 10.1016/j.canlet.2017.05.015. [DOI] [PubMed] [Google Scholar]
191.Guo L, Zheng J, Zhang J, Wang H, Shao G, Teng L. Knockdown of TAZ modifies triple-negative breast cancer cell sensitivity to EGFR inhibitors by regulating YAP expression. Oncol Rep. 2016;36(2):729–36. doi: 10.3892/or.2016.4875. [DOI] [PubMed] [Google Scholar]
192.Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q. et al. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res. 2015;21(11):2580–90. doi: 10.1158/1078-0432.CCR-14-2191. [DOI] [PMC free article] [PubMed] [Google Scholar]
193.Ma K, Xu Q, Wang S, Zhang W, Liu M, Liang S. et al. Nuclear accumulation of Yes-Associated Protein (YAP) maintains the survival of doxorubicin-induced senescent cells by promoting survivin expression. Cancer Lett. 2016;375(1):84–91. doi: 10.1016/j.canlet.2016.02.045. [DOI] [PubMed] [Google Scholar]
194.Song J, Xie LX, Zhang XY, Hu P, Long MF, Xiong F. et al. Role of YAP in lung cancer resistance to cisplatin. Oncol Lett. 2018;16(3):3949–54. doi: 10.3892/ol.2018.9141. [DOI] [PMC free article] [PubMed] [Google Scholar]
195.Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M. et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014;110(7):1698–704. doi: 10.1038/bjc.2014.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
196.Hagenbeek TJ, Zbieg JR, Hafner M, Mroue R, Lacap JA, Sodir NM. et al. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Nat Cancer. 2023;4(6):812–28. doi: 10.1038/s43018-023-00577-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
197.Tang TT, Konradi AW, Feng Y, Peng X, Ma M, Li J. et al. Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma. Mol Cancer Ther. 2021;20(6):986–98. doi: 10.1158/1535-7163.MCT-20-0717. [DOI] [PubMed] [Google Scholar]
198.Kaneda A, Seike T, Danjo T, Nakajima T, Otsubo N, Yamaguchi D. et al. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma. Am J Cancer Research. 2020;10(12):4399–415. [PMC free article] [PubMed] [Google Scholar]
199.Zagiel B, Melnyk P, Cotelle P. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present) Expert Opin Ther Pat. 2022;32(8):899–912. doi: 10.1080/13543776.2022.2096436. [DOI] [PubMed] [Google Scholar]

[B1] 1.Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell. 2020;37(4):443–55. doi: 10.1016/j.ccell.2020.03.017. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B2] 2.Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12(1):134. doi: 10.1186/s13045-019-0818-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B3] 3.Yu S, Zhang C, Xie KP. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188461. doi: 10.1016/j.bbcan.2020.188461. [DOI] [PubMed] [Google Scholar]

[B4] 4.Gusyatiner O, Hegi ME. Glioma epigenetics: From subclassification to novel treatment options. Semin in Cancer Biol. 2018;51:50–8. doi: 10.1016/j.semcancer.2017.11.010. [DOI] [PubMed] [Google Scholar]

[B5] 5.Bao MH, Wong CC. Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. Cells. 2021;10(7):1715. doi: 10.3390/cells10071715. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B6] 6.Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N. et al. Drug resistance in cancer: an overview. Cancers (Basel) 2014;6(3):1769–92. doi: 10.3390/cancers6031769. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B7] 7.Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J. et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747–61. doi: 10.1101/gad.1602907. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B8] 8.Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N. et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell. 2013;154(5):1047–59. doi: 10.1016/j.cell.2013.07.042. [DOI] [PubMed] [Google Scholar]

[B9] 9.Panciera T, Azzolin L, Cordenonsi M, Piccolo S. Mechanobiology of YAP and TAZ in physiology and disease. Nat Rev Mol Cell Biol. 2017;18(12):758–70. doi: 10.1038/nrm.2017.87. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B10] 10.Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI. et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013;15(6):637–46. doi: 10.1038/ncb2756. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B11] 11.Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005;122(3):421–34. doi: 10.1016/j.cell.2005.06.007. [DOI] [PubMed] [Google Scholar]

[B12] 12.Zhao B, Ye X, Yu J, Li L, Li W, Li S. et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962–71. doi: 10.1101/gad.1664408. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B13] 13.Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S. et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Bio Chem. 2009;284(20):13355–62. doi: 10.1074/jbc.M900843200. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B14] 14.Zhao B, Kim J, Ye X, Lai ZC, Guan KL. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Cancer Res. 2009;69(3):1089–98. doi: 10.1158/0008-5472.CAN-08-2997. [DOI] [PubMed] [Google Scholar]

[B15] 15.Li H, Wu BK, Kanchwala M, Cai J, Wang L. et al. YAP/TAZ drives cell proliferation and tumour growth via a polyamine-eIF5A hypusination-LSD1 axis. Nat Cell Biol. 2022;24(3):373–83. doi: 10.1038/s41556-022-00848-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B16] 16.Yuan Y, Li D, Li H, Wang L, Tian G, Dong Y. YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells. Mol Med Rep. 2016;13(1):237–42. doi: 10.3892/mmr.2015.4550. [DOI] [PubMed] [Google Scholar]

[B17] 17.Zhao M, Zhang Y, Jiang Y, Wang K, Wang X, Zhou D. et al. YAP promotes autophagy and progression of gliomas via upregulating HMGB1. J Exp Clin Cancer Res. 2021;40(1):99. doi: 10.1186/s13046-021-01897-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B18] 18.Liu H, Mei D, Xu P, Wang H, Wang Y. YAP promotes gastric cancer cell survival and migration/invasion via the ERK/endoplasmic reticulum stress pathway. Oncol Lett. 2019;18(6):6752–8. doi: 10.3892/ol.2019.11049. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B19] 19.Zhou Y, Wang Y, Zhou W, Chen T, Wu Q, Chutturghoon VK. et al. YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway. Cancer Cell Int. 2019;19:179. doi: 10.1186/s12935-019-0898-7. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B20] 20.Marti P, Stein C, Blumer T, Abraham Y, Dill MT, Pikiolek M. et al. YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. Hepatology. 2015;62(5):1497–510. doi: 10.1002/hep.27992. [DOI] [PubMed] [Google Scholar]

[B21] 21.Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G. et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene. 2015;34(6):681–90. doi: 10.1038/onc.2014.5. [DOI] [PubMed] [Google Scholar]

[B22] 22.Ge L, Li DS, Chen F, Feng JD, Li B, Wang TJ. TAZ overexpression is associated with epithelial-mesenchymal transition in cisplatin-resistant gastric cancer cells. Int J Oncol. 2017;51(1):307–15. doi: 10.3892/ijo.2017.3998. [DOI] [PubMed] [Google Scholar]

[B23] 23.Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B. et al. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol. 2015;17(9):1218–27. doi: 10.1038/ncb3216. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B24] 24.Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem. 2009;284(21):14347–58. doi: 10.1074/jbc.M901568200. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B25] 25.Shao D, Zhai P, Del Re DP, Sciarretta S, Yabuta N, Nojima H. et al. A functional interaction between Hippo-YAP signalling and FoxO1 mediates the oxidative stress response. Nat Commun. 2014;5:3315. doi: 10.1038/ncomms4315. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B26] 26.Chen Q, Zhang N, Gray RS, Li H, Ewald AJ, Zahnow CA. et al. A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev. 2014;28(5):432–7. doi: 10.1101/gad.233676.113. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B27] 27.Zhang Y, Wang Y, Zhou D, Wang K, Wang X, Wang X. et al. Radiation-induced YAP activation confers glioma radioresistance via promoting FGF2 transcription and DNA damage repair. Oncogene. 2021;40(27):4580–91. doi: 10.1038/s41388-021-01878-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B28] 28.Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol. 2003;5(10):914–20. doi: 10.1038/ncb1050. [DOI] [PubMed] [Google Scholar]

[B29] 29.Chan EH, Nousiainen M, Chalamalasetty RB, Schäfer A, Nigg EA, Silljé HH. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene. 2005;24(12):2076–86. doi: 10.1038/sj.onc.1208445. [DOI] [PubMed] [Google Scholar]

[B30] 30.Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell. 2013;154(6):1342–55. doi: 10.1016/j.cell.2013.08.025. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B31] 31.Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N. Kibra is a regulator of the Salvador/Warts/Hippo signaling network. Dev Cell. 2010;18(2):300–8. doi: 10.1016/j.devcel.2009.12.011. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B32] 32.Yu J, Zheng Y, Dong J, Klusza S, Deng WM, Pan D. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev Cell. 2010;18(2):288–99. doi: 10.1016/j.devcel.2009.12.012. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B33] 33.Baumgartner R, Poernbacher I, Buser N, Hafen E, Stocker H. The WW domain protein Kibra acts upstream of Hippo in Drosophila. Dev Cell. 2010;18(2):309–16. doi: 10.1016/j.devcel.2009.12.013. [DOI] [PubMed] [Google Scholar]

[B34] 34.Callus BA, Verhagen AM, Vaux DL. Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and phosphorylation. FEBS J. 2006;273(18):4264–76. doi: 10.1111/j.1742-4658.2006.05427.x. [DOI] [PubMed] [Google Scholar]

[B35] 35.Praskova M, Khoklatchev A, Ortiz-Vega S, Avruch J. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem J. 2004;381(Pt 2):453–62. doi: 10.1042/BJ20040025. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B36] 36.Oh HJ, Lee KK, Song SJ, Jin MS, Song MS, Lee JH. et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res. 2006;66(5):2562–9. doi: 10.1158/0008-5472.CAN-05-2951. [DOI] [PubMed] [Google Scholar]

[B37] 37.Dhanaraman T, Singh S, Killoran RC, Singh A, Xu X, Shifman JM. et al. RASSF effectors couple diverse RAS subfamily GTPases to the Hippo pathway. Sci Signal. 2020;13(653):eabb4778. doi: 10.1126/scisignal.abb4778. [DOI] [PubMed] [Google Scholar]

[B38] 38.Hoa L, Kulaberoglu Y, Gundogdu R, Cook D, Mavis M, Gomez M. et al. The characterisation of LATS2 kinase regulation in Hippo-YAP signalling. Cell Signal. 2016;28(5):488–97. doi: 10.1016/j.cellsig.2016.02.012. [DOI] [PubMed] [Google Scholar]

[B39] 39.Hergovich A, Schmitz D, Hemmings BA. The human tumour suppressor LATS1 is activated by human MOB1 at the membrane. Biochem Biophys Res Commun. 2006;345(1):50–8. doi: 10.1016/j.bbrc.2006.03.244. [DOI] [PubMed] [Google Scholar]

[B40] 40.Zheng Y, Wang W, Liu B, Deng H, Uster E, Pan D. Identification of Happyhour/MAP4K as Alternative Hpo/Mst-like Kinases in the Hippo Kinase Cascade. Dev Cell. 2015;34(6):642–55. doi: 10.1016/j.devcel.2015.08.014. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B41] 41.Meng Z, Moroishi T, Mottier-Pavie V, Plouffe SW, Hansen CG, Hong AW. et al. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat Commun. 2015;6:8357. doi: 10.1038/ncomms9357. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B42] 42.Li Q, Li S, Mana-Capelli S, Roth Flach RJ, Danai LV, Amcheslavsky A. et al. The conserved misshapen-warts-Yorkie pathway acts in enteroblasts to regulate intestinal stem cells in Drosophila. Dev Cell. 2014;31(3):291–304. doi: 10.1016/j.devcel.2014.09.012. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B43] 43.Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP) Genes Dev. 2010;24(1):72–85. doi: 10.1101/gad.1843810. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B44] 44.Li FL, Fu V, Liu G, Tang T, Konradi AW, Peng X. et al. Hippo pathway regulation by phosphatidylinositol transfer protein and phosphoinositides. Nat Chem Biol. 2022;18(10):1076–1086. doi: 10.1038/s41589-022-01061-z. [DOI] [PubMed] [Google Scholar]

[B45] 45.Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M. et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 2000;19(24):6778–91. doi: 10.1093/emboj/19.24.6778. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B46] 46.Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev. 2001;15(10):1229–41. doi: 10.1101/gad.888601. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B47] 47.Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D. et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem. 2010;285(48):37159–69. doi: 10.1074/jbc.M110.152942. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B48] 48.Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A. et al. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene. 2013;32(17):2220–9. doi: 10.1038/onc.2012.231. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B49] 49.Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J. et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev. 2010;24(11):1106–18. doi: 10.1101/gad.1903310. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B50] 50.Liu X, Yang N, Figel SA, Wilson KE, Morrison CD, Gelman IH. et al. PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene. 2013;32(10):1266–73. doi: 10.1038/onc.2012.147. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B51] 51.Oka T, Remue E, Meerschaert K, Vanloo B, Boucherie C, Gfeller D. et al. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. Biochem J. 2010;432(3):461–72. doi: 10.1042/BJ20100870. [DOI] [PubMed] [Google Scholar]

[B52] 52.Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M. et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014;25(6):831–45. doi: 10.1016/j.ccr.2014.04.016. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B53] 53.Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S. et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 2014;16(4):357–66. doi: 10.1038/ncb2936. [DOI] [PubMed] [Google Scholar]

[B54] 54.Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH. et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150(4):780–91. doi: 10.1016/j.cell.2012.06.037. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B55] 55.Park HW, Kim YC, Yu B, Moroishi T, Mo JS, Plouffe SW. et al. Alternative Wnt Signaling Activates YAP/TAZ. Cell. 2015;162(4):780–94. doi: 10.1016/j.cell.2015.07.013. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B56] 56.Li C, Peng Z, Wang Y, Lam G, Nissen N, Tang J. et al. Epithelial cell transforming 2 is regulated by Yes-associated protein 1 and mediates pancreatic cancer progression and metastasis. Am J Physiol Gastrointest Liver Physiol. 2021;320(3):G380–G395. doi: 10.1152/ajpgi.00185.2020. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B57] 57.Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX. et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015;519(7541):57–62. doi: 10.1038/nature14228. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B58] 58.Levy D, Adamovich Y, Reuven N, Shaul Y. Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell. 2008;29(3):350–61. doi: 10.1016/j.molcel.2007.12.022. [DOI] [PubMed] [Google Scholar]

[B59] 59.Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ. et al. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151(7):1457–73. doi: 10.1016/j.cell.2012.11.026. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B60] 60.Fang L, Teng H, Wang Y, Liao G, Weng L, Li Y. et al. SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis. Cancer Cell. 2018;34(1):103–18. doi: 10.1016/j.ccell.2018.06.002. [DOI] [PubMed] [Google Scholar]

[B61] 61.Peng C, Zhu Y, Zhang W, Liao Q, Chen Y, Zhao X. et al. Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation. Mol Cell. 2017;68(3):591–604. doi: 10.1016/j.molcel.2017.10.010. [DOI] [PubMed] [Google Scholar]

[B62] 62.Kim E, Kang JG, Kang MJ, Park JH, Kim YJ, Kweon TH. et al. O-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity. Proc Natl Acad Sci U S A. 2020;117(25):14259–69. doi: 10.1073/pnas.1913469117. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B63] 63.Yang S, Xu W, Liu C, Jin J, Li X, Jiang Y. et al. LATS1 K751 acetylation blocks activation of Hippo signalling and switches LATS1 from a tumor suppressor to an oncoprotein. Sci China Life Sci. 2022;65(1):129–41. doi: 10.1007/s11427-020-1914-3. [DOI] [PubMed] [Google Scholar]

[B64] 64.Tang J, Tian Z, Liao X, Wu G. SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer. Int J Biol Sci. 2021;17(2):417–29. doi: 10.7150/ijbs.54194. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B65] 65.Huo X, Zhang QI, Liu AM, Tang C, Gong Y, Bian J. et al. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma. Oncol Rep. 2013;29(2):840–6. doi: 10.3892/or.2012.2176. [DOI] [PubMed] [Google Scholar]

[B66] 66.Wang DY, Wu YN, Huang JQ, Wang W, Xu M, Jia JP. et al. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance. Chin J Cancer. 2016;35:47. doi: 10.1186/s40880-016-0109-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B67] 67.Tao Y, Shan L, Xu X, Jiang H, Chen R, Qian Z. et al. Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma. J Cancer. 2018;9(21):3962–70. doi: 10.7150/jca.25909. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B68] 68.Dai XY, Zhuang LH, Wang DD, Zhou TY, Chang LL, Gai RH. et al. Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells. Oncotarget. 2016;7(6):6933–47. doi: 10.18632/oncotarget.6903. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B69] 69.Wu Q, Guo J, Liu Y, Zheng Q, Li X, Wu C. et al. YAP drives fate conversion and chemoresistance of small cell lung cancer. Sci Adv. 2021;7(40):eabg1850. doi: 10.1126/sciadv.abg1850. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B70] 70.Xiao L, Shi XY, Zhang Y, Zhu Y, Zhu L, Tian W. et al. YAP induces cisplatin resistance through activation of autophagy in human ovarian carcinoma cells. Onco Targets Ther. 2016;9:1105–14. doi: 10.2147/OTT.S102837. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B71] 71.Bi L, Ma F, Tian R, Zhou Y, Lan W, Song Q. et al. AJUBA increases the cisplatin resistance through hippo pathway in cervical cancer. Gene. 2018;644:148–54. doi: 10.1016/j.gene.2017.11.017. [DOI] [PubMed] [Google Scholar]

[B72] 72.Xu W, Wei Y, Li Y, Yin Y, Yuan W, Yang Y. et al. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma. Oncol Rep. 2017;38(3):1815–21. doi: 10.3892/or.2017.5847. [DOI] [PubMed] [Google Scholar]

[B73] 73.Li C, Wang Q, Luo Y, Xiang J. TAZ Regulates the Cisplatin Resistance of Epithelial Ovarian Cancer Cells via the ANGPTL4/SOX2 Axis. Anal Cell Pathol (Amst) 2022;2022:5632164. doi: 10.1155/2022/5632164. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B74] 74.Jiang Z, Chen X, Chen K, Sun L, Gao L, Zhou C. et al. YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine. Nutrients. 2016;8(10):546. doi: 10.3390/nu8100546. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B75] 75.He Z, Chen D, Wu J, Sui C, Deng X, Zhang P. et al. Yes associated protein 1 promotes resistance to 5-fluorouracil in gastric cancer by regulating GLUT3-dependent glycometabolism reprogramming of tumor-associated macrophages. Arch Biochem Biophys. 2021;702:108838. doi: 10.1016/j.abb.2021.108838. [DOI] [PubMed] [Google Scholar]

[B76] 76.Gujral TS, Kirschner MW. Hippo pathway mediates resistance to cytotoxic drugs. Proc Natl Acad Sci U S A. 2017;114(18):E3729–38. doi: 10.1073/pnas.1703096114. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B77] 77.Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming. Drug Resist Updat. 2021;54:100742. doi: 10.1016/j.drup.2020.100742. [DOI] [PubMed] [Google Scholar]

[B78] 78.Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB. et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 2011;30(25):2810–22. doi: 10.1038/onc.2011.8. [DOI] [PubMed] [Google Scholar]

[B79] 79.Li W, Cao Y, Xu J, Wang Y, Li W, Wang Q. et al. YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer. J Expe Clin Cancer Res. 2017;36(1):144. doi: 10.1186/s13046-017-0612-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B80] 80.Lai D, Ho KC, Hao Y, Yang X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 2011;71(7):2728–38. doi: 10.1158/0008-5472.CAN-10-2711. [DOI] [PubMed] [Google Scholar]

[B81] 81.Ma J, Fan Z, Tang Q, Xia H, Zhang T, Bi F. Aspirin attenuates YAP and β-catenin expression by promoting β-TrCP to overcome docetaxel and vinorelbine resistance in triple-negative breast cancer. Cell Death Dis. 2020;11(7):530. doi: 10.1038/s41419-020-2719-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B82] 82.Xia Y, Zhang YL, Yu C, Chang T, Fan HY. YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells. PloS one. 2014;9(11):e109575. doi: 10.1371/journal.pone.0109575. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B83] 83.Weiler SME, Pinna F, Wolf T, Lutz T, Geldiyev A, Sticht C. et al. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer. Gastroenterology. 2017;152(8):2037–51.e22. doi: 10.1053/j.gastro.2017.02.018. [DOI] [PubMed] [Google Scholar]

[B84] 84.Pattschull G, Walz S, Gründl M, Schwab M, Rühl E, Baluapuri A. et al. The Myb-MuvB Complex Is Required for YAP-Dependent Transcription of Mitotic Genes. Cell Rep. 2019;27(12):3533–46.e7. doi: 10.1016/j.celrep.2019.05.071. [DOI] [PubMed] [Google Scholar]

[B85] 85.Yang S, Zhang L, Liu M, Chong R, Ding SJ, Chen Y. et al. CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation. Cancer Res. 2013;73(22):6722–33. doi: 10.1158/0008-5472.CAN-13-2049. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B86] 86.Pellosi DS, Paula LB, de Melo MT, Tedesco AC. Targeted and Synergic Glioblastoma Treatment: Multifunctional Nanoparticles Delivering Verteporfin as Adjuvant Therapy for Temozolomide Chemotherapy. Mol Pharm. 2019;16(3):1009–24. doi: 10.1021/acs.molpharmaceut.8b01001. [DOI] [PubMed] [Google Scholar]

[B87] 87.El-Sahli S, Hua K, Sulaiman A, Chambers J, Li L, Farah E. et al. A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature. Cell Death Dis. 2021;12(1):8. doi: 10.1038/s41419-020-03308-w. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B88] 88.Tsimberidou AM. Targeted therapy in cancer. Cancer Chemother Pharmacol. 2015;76(6):1113–32. doi: 10.1007/s00280-015-2861-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B89] 89.Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37(24):3183–99. doi: 10.1038/s41388-018-0171-x. [DOI] [PubMed] [Google Scholar]

[B90] 90.Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508(7494):118–22. doi: 10.1038/nature13121. [DOI] [PubMed] [Google Scholar]

[B91] 91.Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84–7. doi: 10.1126/science.1247005. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B92] 92.Kim MH, Kim J, Hong H, Lee SH, Lee JK, Jung E. et al. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. EMBO J. 2016;35(5):462–78. doi: 10.15252/embj.201592081. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B93] 93.Kim MH, Kim CG, Kim SK, Shin SJ, Choe EA, Park SH. et al. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. Cancer Immunol Res. 2018;6(3):255–66. doi: 10.1158/2326-6066.CIR-17-0320. [DOI] [PubMed] [Google Scholar]

[B94] 94.Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014;24(1):26–34. doi: 10.1016/j.tcb.2013.11.002. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B95] 95.Wang H, Lu B, Castillo J, Zhang Y, Yang Z, McAllister G. et al. Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling. J Biol Chem. 2016;291(29):15256–66. doi: 10.1074/jbc.M116.722967. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B96] 96.Lee JE, Park HS, Lee D, Yoo G, Kim T, Jeon H. et al. Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. Biochem Biophys Res Comm. 2016;474(1):154–60. doi: 10.1016/j.bbrc.2016.04.089. [DOI] [PubMed] [Google Scholar]

[B97] 97.Lee TF, Tseng YC, Nguyen PA, Li YC, Ho CC, Wu CW. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas. Sci Rep. 2018;8(1):271. doi: 10.1038/s41598-017-18527-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B98] 98.Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J. et al. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci Transl Med. 2020;12(559):eaaz4589. doi: 10.1126/scitranslmed.aaz4589. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B99] 99.Ghiso E, Migliore C, Ciciriello V, Morando E, Petrelli A, Corso S. et al. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC. Neoplasia. 2017;19(12):1012–21. doi: 10.1016/j.neo.2017.10.003. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B100] 100.Park HS, Lee DH, Kang DH, Yeo MK, Bae G, Lee D. et al. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma. Cancer Med. 2021;10(4):1405–17. doi: 10.1002/cam4.3734. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B101] 101.Shi J, Li F, Yao X, Mou T, Xu Z, Han Z. et al. The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition. Oncogene. 2018;37(22):3022–38. doi: 10.1038/s41388-018-0204-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B102] 102.Cheng H, Zhang Z, Rodriguez-Barrueco R, Borczuk A, Liu H, Yu J. et al. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells. Oncotarget. 2016;7(20):28976–88. doi: 10.18632/oncotarget.6721. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B103] 103.González-Alonso P, Zazo S, Martín-Aparicio E, Luque M, Chamizo C, Sanz-Álvarez M. et al. The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer. Cancers (Basel) 2020;12(5):1108. doi: 10.3390/cancers12051108. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B104] 104.Coggins GE, Farrel A, Rathi KS, Hayes CM, Scolaro L, Rokita JL. et al. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling. Cancer Res. 2019;79(24):6204–14. doi: 10.1158/0008-5472.CAN-19-1415. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B105] 105.Rao G, Kim IK, Conforti F, Liu J, Zhang YW, Giaccone G. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity. Eur J Cancer. 2018;99:37–48. doi: 10.1016/j.ejca.2018.05.013. [DOI] [PubMed] [Google Scholar]

[B106] 106.Yun MR, Choi HM, Lee YW, Joo HS, Park CW, Choi JW. et al. Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer. EMBO Mol Med. 2019;11(12):e10581. doi: 10.15252/emmm.201910581. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B107] 107.Gobbi G, Donati B, Do Valle IF, Reggiani F, Torricelli F, Remondini D. et al. The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. Oncogene. 2019;38(42):6801–17. doi: 10.1038/s41388-019-0924-1. [DOI] [PubMed] [Google Scholar]

[B108] 108.Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8(9):1069–86. doi: 10.1158/2159-8290.CD-18-0367. [DOI] [PubMed] [Google Scholar]

[B109] 109.Liu X, Yang L, Tan X. PD-1/PD-L1 pathway: A double-edged sword in periodontitis. Biomed Pharmacother. 2023;159:114215. doi: 10.1016/j.biopha.2023.114215. [DOI] [PubMed] [Google Scholar]

[B110] 110.Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335–7. doi: 10.1172/JCI83871. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B111] 111.Rodríguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E. et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881–95. doi: 10.1016/j.annonc.2021.04.008. [DOI] [PubMed] [Google Scholar]

[B112] 112.Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108–21. doi: 10.1056/NEJMoa1809615. [DOI] [PubMed] [Google Scholar]

[B113] 113.Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E. et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020–31. doi: 10.1056/NEJMoa1910231. [DOI] [PubMed] [Google Scholar]

[B114] 114.Lee BS, Park DI, Lee DH, Lee JE, Yeo MK, Park YH. et al. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. Biochem Biophys Res Commun. 2017;491(2):493–9. doi: 10.1016/j.bbrc.2017.07.007. [DOI] [PubMed] [Google Scholar]

[B115] 115.Janse van Rensburg HJ, Azad T, Ling M, Hao Y, Snetsinger B, Khanal P. et al. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1. Cancer Res. 2018;78(6):1457–70. doi: 10.1158/0008-5472.CAN-17-3139. [DOI] [PubMed] [Google Scholar]

[B116] 116.Ni X, Tao J, Barbi J, Chen Q, Park BV, Li Z. et al. YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity. Cancer Discov. 2018;8(8):1026–43. doi: 10.1158/2159-8290.CD-17-1124. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B117] 117.Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S. et al. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov. 2016;6(1):80–95. doi: 10.1158/2159-8290.CD-15-0224. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B118] 118.Murakami S, Shahbazian D, Surana R, Zhang W, Chen H, Graham GT. et al. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene. 2017;36(9):1232–44. doi: 10.1038/onc.2016.288. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B119] 119.Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395–417. doi: 10.1038/s41571-020-0341-y. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B120] 120.Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21(1):47. doi: 10.1186/s12943-022-01530-y. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B121] 121.Cheng Y, Mao M, Lu Y. The biology of YAP in programmed cell death. Biomark Res. 2022;10(1):34. doi: 10.1186/s40364-022-00365-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B122] 122.Yan B, Li T, Shen L, Zhou Z, Liu X, Wang X. et al. Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition. Biochem Biophys Res Commun. 2019;515(2):275–81. doi: 10.1016/j.bbrc.2019.05.143. [DOI] [PubMed] [Google Scholar]

[B123] 123.Wang J, Chen M, Wang M, Zhao W, Zhang C, Liu X. et al. The novel ER stress inducer Sec C triggers apoptosis by sulfating ER cysteine residues and degrading YAP via ER stress in pancreatic cancer cells. Acta Pharm Sinica B. 2022;12(1):210–27. doi: 10.1016/j.apsb.2021.07.004. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B124] 124.Su M, Zhan L, Zhang Y, Zhang J. Yes-activated protein promotes primary resistance of BRAF V600E mutant metastatic colorectal cancer cells to mitogen-activated protein kinase pathway inhibitors. J Gastrointest Oncol. 2021;12(3):953–63. doi: 10.21037/jgo-21-258. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B125] 125.Ma L, Yang F, Wu X, Mao C, Guo L, Miao T. et al. Structural basis and molecular mechanism of biased GPBAR signaling in regulating NSCLC cell growth via YAP activity. Proc Natl Acad Sci U S A. 2022;119(29):e2117054119. doi: 10.1073/pnas.2117054119. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B126] 126.Song Y, Sun Y, Lei Y, Yang K, Tang R. YAP1 promotes multidrug resistance of small cell lung cancer by CD74-related signaling pathways. Cancer Med. 2020;9(1):259–68. doi: 10.1002/cam4.2668. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B127] 127.Patrick S, Gowda P, Lathoria K, Suri V, Sen E. YAP1-mediated regulation of mitochondrial dynamics in IDH1 mutant gliomas. J Cell Sci. 2021;134(22):jcs259188. doi: 10.1242/jcs.259188. [DOI] [PubMed] [Google Scholar]

[B128] 128.Li H, He F, Zhao X, Zhang Y, Chu X, Hua C, YAP Inhibits the Apoptosis and Migration of Human Rectal Cancer Cells via Suppression of JNK-Drp1-Mitochondrial Fission-HtrA2/Omi Pathways. Cell Physiol Biochem. 2017. 44(5) 2073-89. [DOI] [PubMed]

[B129] 129.He L, Yuan L, Yu W, Sun Y, Jiang D, Wang X. et al. A Regulation Loop between YAP and NR4A1 Balances Cell Proliferation and Apoptosis. Cell Rep. 2020;33(3):108284. doi: 10.1016/j.celrep.2020.108284. [DOI] [PubMed] [Google Scholar]

[B130] 130.Han Y, Zhang X, Guan M, Huo C, Yu C, Hu B. et al. RASSF4 inhibits cell proliferation and increases drug sensitivity in colorectal cancer through YAP/Bcl-2 pathway. J Cell Mol Med. 2022;26(12):3538–47. doi: 10.1111/jcmm.17395. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B131] 131.Yan H, Qiu C, Sun W, Gu M, Xiao F, Zou J. et al. Yap regulates gastric cancer survival and migration via SIRT1/Mfn2/mitophagy. Oncol Rep. 2018;39(4):1671–81. doi: 10.3892/or.2018.6252. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]

[B132] 132.Li Y, Zhu X, Yang M, Wang Y, Li J, Fang J. et al. YAP/TEAD4-induced KIF4A contributes to the progression and worse prognosis of esophageal squamous cell carcinoma. Mol Carcinog. 2021;60(7):440–54. doi: 10.1002/mc.23303. [DOI] [PubMed] [Google Scholar]

[B133] 133.Zhao Q, Jia X, Zhang Y, Dong Y, Lei Y, Tan X. et al. Tetrandrine induces apoptosis in human neuroblastoma through regulating the Hippo/YAP signaling pathway. Biochem Biophys Res Commun. 2019;513(4):846–51. doi: 10.1016/j.bbrc.2019.04.075. [DOI] [PubMed] [Google Scholar]

[B134] 134.Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L. et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. 2016;35(12):1541–53. doi: 10.1038/onc.2015.219. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B135] 135.Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A. et al. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 2020;37(1):104–22.e12. doi: 10.1016/j.ccell.2019.12.006. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B136] 136.Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72. doi: 10.1016/j.cell.2012.03.042. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B137] 137.Vucetic M, Daher B, Cassim S, Meira W, Pouyssegur J. Together we stand, apart we fall: how cell-to-cell contact/interplay provides resistance to ferroptosis. Cell Death Dis. 2020;11(9):789. doi: 10.1038/s41419-020-02994-w. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B138] 138.Battaglia AM, Chirillo R, Aversa I, Sacco A, Costanzo F, Biamonte F. Ferroptosis and Cancer: Mitochondria Meet the "Iron Maiden" Cell Death. Cells. 2020;9(6):1505. doi: 10.3390/cells9061505. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B139] 139.Chen X, Kang R, Kroemer G, Tang D. Ferroptosis in infection, inflammation, and immunity. J Exp Med. 2021;218(6):e20210518. doi: 10.1084/jem.20210518. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B140] 140.Wu X, Li Y, Zhang S, Zhou X. Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics. 2021;11(7):3052–9. doi: 10.7150/thno.54113. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B141] 141.Xl L, Gy Z, R G, N C. Ferroptosis in sepsis: The mechanism, the role and the therapeutic potential. Front Immunol. 2022;13:956361. doi: 10.3389/fimmu.2022.956361. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B142] 142.Zhu G, Murshed A, Li H, Ma J, Zhen N, Ding M. et al. O-GlcNAcylation enhances sensitivity to RSL3-induced ferroptosis via the YAP/TFRC pathway in liver cancer. Cell Death Discov. 2021;7(1):83. doi: 10.1038/s41420-021-00468-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B143] 143.Qin Y, Pei Z, Feng Z, Lin P, Wang S, Li Y. et al. Oncogenic Activation of YAP Signaling Sensitizes Ferroptosis of Hepatocellular Carcinoma via ALOXE3-Mediated Lipid Peroxidation Accumulation. Front Cell Dev Biol. 2021;9:751593. doi: 10.3389/fcell.2021.751593. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B144] 144.Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A. 2016;113(34):E4966–75. doi: 10.1073/pnas.1603244113. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B145] 145.Wu J, Minikes AM, Gao M, Bian H, Li Y, Stockwell BR. et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature. 2019;572(7769):402–6. doi: 10.1038/s41586-019-1426-6. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B146] 146.Yang WH, Ding CC, Sun T, Rupprecht G, Lin CC, Hsu D. et al. The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma. Cell Rep. 2019;28(10):2501–8.e4. doi: 10.1016/j.celrep.2019.07.107. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B147] 147.Yang WH, Huang Z, Wu J, Ding CC, Murphy SK, Chi JT. A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer. Mol Cancer Res. 2020;18(1):79–90. doi: 10.1158/1541-7786.MCR-19-0691. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B148] 148.Ye S, Xu M, Zhu T, Chen J, Shi S, Jiang H. et al. Cytoglobin promotes sensitivity to ferroptosis by regulating p53-YAP1 axis in colon cancer cells. J Cell Mol Med. 2021;25(7):3300–11. doi: 10.1111/jcmm.16400. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B149] 149.Gao R, Kalathur RKR, Coto-Llerena M, Ercan C, Buechel D, Shuang S. et al. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med. 2021;13(12):e14351. doi: 10.15252/emmm.202114351. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B150] 150.Zhang Y, Li Y, Qiu Q, Chen Z, Du Y, Liu X. MITD1 Deficiency Suppresses Clear Cell Renal Cell Carcinoma Growth and Migration by Inducing Ferroptosis through the TAZ/SLC7A11 Pathway. Oxid Med Cell longev. 2022;2022:7560569. doi: 10.1155/2022/7560569. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B151] 151.Zhang X, Yu K, Ma L, Qian Z, Tian X, Miao Y. et al. Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma. Theranostics. 2021;11(12):5650–74. doi: 10.7150/thno.55482. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B152] 152.Wang Y, Qiu S, Wang H, Cui J, Tian X, Miao Y. et al. Transcriptional Repression of Ferritin Light Chain Increases Ferroptosis Sensitivity in Lung Adenocarcinoma. Front Cell Dev Biol. 2021;9:719187. doi: 10.3389/fcell.2021.719187. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B153] 153.Mizushima N, Levine B. Autophagy in Human Diseases. New Engl J Med. 2020;383(16):1564–76. doi: 10.1056/NEJMra2022774. [DOI] [PubMed] [Google Scholar]

[B154] 154.Klionsky DJ, Petroni G, Amaravadi RK, Baehrecke EH, Ballabio A, Boya P. et al. Autophagy in major human diseases. EMBO J. 2021;40(19):e108863. doi: 10.15252/embj.2021108863. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B155] 155.Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528–42. doi: 10.1038/nrc.2017.53. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B156] 156.White E, Mehnert JM, Chan CS. Autophagy, Metabolism, and Cancer. Clin Cancer Res. 2015;21(22):5037–46. doi: 10.1158/1078-0432.CCR-15-0490. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B157] 157.White E. The role for autophagy in cancer. J Clin Invest. 2015;125(1):42–6. doi: 10.1172/JCI73941. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B158] 158.Majeed ST, Majeed R, Andrabi KI. Expanding the view of the molecular mechanisms of autophagy pathway. J Cell Physiol. 2022;237(8):3257–77. doi: 10.1002/jcp.30819. [DOI] [PubMed] [Google Scholar]

[B159] 159.Marsh T, Debnath J. Autophagy suppresses breast cancer metastasis by degrading NBR1. Autophagy. 2020;16(6):1164–5. doi: 10.1080/15548627.2020.1753001. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B160] 160.Kudo Y, Sugimoto M, Arias E, Kasashima H, Cordes T, Linares JF. et al. PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression. Cancer Cell. 2020;38(2):247–62.e11. doi: 10.1016/j.ccell.2020.05.018. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B161] 161.Miao CC, Hwang W, Chu LY, Yang LH, Ha CT, Chen PY. et al. LC3A-mediated autophagy regulates lung cancer cell plasticity. Autophagy. 2022;18(4):921–34. doi: 10.1080/15548627.2021.1964224. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B162] 162.Yamamoto K, Venida A, Yano J, Biancur DE, Kakiuchi M, Gupta S. et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581(7806):100–5. doi: 10.1038/s41586-020-2229-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B163] 163.Wang D, He J, Huang B, Liu S, Zhu H, Xu T. Emerging role of the Hippo pathway in autophagy. Cell Death Dis. 2020;11(10):880. doi: 10.1038/s41419-020-03069-6. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B164] 164.Wang CZ, Yan GX, Dong DS, Xin H, Liu ZY. LncRNA-ATB promotes autophagy by activating Yes-associated protein and inducing autophagy-related protein 5 expression in hepatocellular carcinoma. World J Gastroenterol. 2019;25(35):5310–22. doi: 10.3748/wjg.v25.i35.5310. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B165] 165.Sun T, Peng H, Mao W, Ma L, Liu H, Mai J. et al. Autophagy-mediated negative feedback attenuates the oncogenic activity of YAP in pancreatic cancer. Int J Biol Sci. 2021;17(13):3634–45. doi: 10.7150/ijbs.61795. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B166] 166.Lee YA, Noon LA, Akat KM, Ybanez MD, Lee TF, Berres ML. et al. Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nature Commun. 2018;9(1):4962. doi: 10.1038/s41467-018-07338-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B167] 167.Ma F, Ding MG, Lei YY, Luo LH, Jiang S, Feng YH. et al. SKIL facilitates tumorigenesis and immune escape of NSCLC via upregulating TAZ/autophagy axis. Cell Death Dis. 2020;11(12):1028. doi: 10.1038/s41419-020-03200-7. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B168] 168.Jiang Y, Ji F, Liu Y, He M, Zhang Z, Yang J. et al. Cisplatin-induced autophagy protects breast cancer cells from apoptosis by regulating yes-associated protein. Oncol Rep. 2017;38(6):3668–76. doi: 10.3892/or.2017.6035. [DOI] [PubMed] [Google Scholar]

[B169] 169.Rivera-Reyes A, Ye S, G EM, Egolf S, G EC, Chor S. et al. YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma. Cell Death Dis. 2018;9(11):1108. doi: 10.1038/s41419-018-1142-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B170] 170.Zhou W, Weng J, Wu K, Xu X, Wang H, Zhang J. et al. Silencing of TAZ inhibits the motility of hepatocellular carcinoma cells through autophagy induction. Cancer Manag Res. 2019;11:8743–53. doi: 10.2147/CMAR.S215466. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B171] 171.Xu W, Zhang M, Li Y, Wang Y, Wang K, Chen Q. et al. YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas. Cancer Cell Int. 2021;21(1):30. doi: 10.1186/s12935-020-01688-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B172] 172.Jin L, Chen Y, Cheng D, He Z, Shi X, Du B. et al. YAP inhibits autophagy and promotes progression of colorectal cancer via upregulating Bcl-2 expression. Cell Death Dis. 2021;12(5):457. doi: 10.1038/s41419-021-03722-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B173] 173.Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity. Mol Cell. 2021;81(22):4579–90. doi: 10.1016/j.molcel.2021.09.003. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B174] 174.Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660–5. doi: 10.1038/nature15514. [DOI] [PubMed] [Google Scholar]

[B175] 175.Jia Y, Wang X, Deng Y, Li S, Xu X, Qin Y. et al. Pyroptosis Provides New Strategies for the Treatment of Cancer. J Cancer. 2023;14(1):140–51. doi: 10.7150/jca.77965. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B176] 176.Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C. et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A. 2010;107(50):21635–40. doi: 10.1073/pnas.1016814108. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B177] 177.Van Gorp H, Lamkanfi M. The emerging roles of inflammasome-dependent cytokines in cancer development. EMBO Rep. 2019;20(6):e47575. doi: 10.15252/embr.201847575. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B178] 178.Wang WJ, Chen D, Jiang MZ, Xu B, Li XW, Chu Y. et al. Downregulation of gasdermin D promotes gastric cancer proliferation by regulating cell cycle-related proteins. J Dig Dis. 2018;19(2):74–83. doi: 10.1111/1751-2980.12576. [DOI] [PubMed] [Google Scholar]

[B179] 179.Li F, Xia Q, Ren L, Nie Y, Ren H, Guo X. et al. GSDME Increases Chemotherapeutic Drug Sensitivity by Inducing Pyroptosis in Retinoblastoma Cells. Oxid Med Cell Longev. 2022;2022:2371807. doi: 10.1155/2022/2371807. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B180] 180.Liang L, Yan B, Liu Y, Jiang S, He H, Huang J. et al. FOXP3 Contributes to TMZ Resistance, Prognosis, and Immune Infiltration in GBM from a Novel Pyroptosis-Associated Risk Signature. Dis Markers. 2022;2022:4534080. doi: 10.1155/2022/4534080. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B181] 181.Cheng Z, Li Z, Gu L, Li L, Gao Q, Zhang X. et al. Ophiopogonin B alleviates cisplatin resistance of lung cancer cells by inducing Caspase-1/GSDMD dependent pyroptosis. J Cancer. 2022;13(2):715–27. doi: 10.7150/jca.66432. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B182] 182.Zheng ZY, Yang PL, Li RY, Liu LX, Xu XE, Liao LD. et al. STAT3β disrupted mitochondrial electron transport chain enhances chemosensitivity by inducing pyroptosis in esophageal squamous cell carcinoma. Cancer Lett. 2021;522:171–83. doi: 10.1016/j.canlet.2021.09.035. [DOI] [PubMed] [Google Scholar]

[B183] 183.Li S, Chen P, Cheng B, Liu Y, Zhang X, Xu Q. et al. Pyroptosis predicts immunotherapy outcomes across multiple cancer types. Clin Immunol. 2022;245:109163. doi: 10.1016/j.clim.2022.109163. [DOI] [PubMed] [Google Scholar]

[B184] 184.Wang M, Wu M, Liu X, Shao S, Huang J, Liu B. et al. Pyroptosis Remodeling Tumor Microenvironment to Enhance Pancreatic Cancer Immunotherapy Driven by Membrane Anchoring Photosensitizer. Adv Sci (Weinh) 2022;9(29):e2202914. doi: 10.1002/advs.202202914. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B185] 185.Zhang T, Lu L, Li M, Zhang D, Yu P, Zhang X. et al. Exosome from BMMSC attenuates cardiopulmonary bypass-induced acute lung injury via YAP/β-catenin pathway: down-regulation of pyroptosis. Stem Cells. 2022;40(12):1122–1133. doi: 10.1093/stmcls/sxac063. [DOI] [PubMed] [Google Scholar]

[B186] 186.Hong L, Zha Y, Wang C, Qiao S, An J. Folic Acid Alleviates High Glucose and Fat-Induced Pyroptosis via Inhibition of the Hippo Signal Pathway on H9C2 Cells. Front Mol Biosci. 2021;8:698698. doi: 10.3389/fmolb.2021.698698. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B187] 187.García-Gil A, Galán-Enríquez CS, Pérez-López A, Nava P, Alpuche-Aranda C, Ortiz-Navarrete V. SopB activates the Akt-YAP pathway to promote Salmonella survival within B cells. Virulence. 2018;9(1):1390–402. doi: 10.1080/21505594.2018.1509664. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B188] 188.Cui J, Zhou Z, Yang H, Jiao F, Li N, Gao Y. et al. MST1 Suppresses Pancreatic Cancer Progression via ROS-Induced Pyroptosis. Mol Cancer Res. 2019;17(6):1316–25. doi: 10.1158/1541-7786.MCR-18-0910. [DOI] [PubMed] [Google Scholar]

[B189] 189.Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA. et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26(12):1300–5. doi: 10.1101/gad.192856.112. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B190] 190.Zhao X, Wang X, Fang L, Lan C, Zheng X, Wang Y. et al. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. Cancer Lett. 2017;402:61–70. doi: 10.1016/j.canlet.2017.05.015. [DOI] [PubMed] [Google Scholar]

[B191] 191.Guo L, Zheng J, Zhang J, Wang H, Shao G, Teng L. Knockdown of TAZ modifies triple-negative breast cancer cell sensitivity to EGFR inhibitors by regulating YAP expression. Oncol Rep. 2016;36(2):729–36. doi: 10.3892/or.2016.4875. [DOI] [PubMed] [Google Scholar]

[B192] 192.Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q. et al. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res. 2015;21(11):2580–90. doi: 10.1158/1078-0432.CCR-14-2191. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B193] 193.Ma K, Xu Q, Wang S, Zhang W, Liu M, Liang S. et al. Nuclear accumulation of Yes-Associated Protein (YAP) maintains the survival of doxorubicin-induced senescent cells by promoting survivin expression. Cancer Lett. 2016;375(1):84–91. doi: 10.1016/j.canlet.2016.02.045. [DOI] [PubMed] [Google Scholar]

[B194] 194.Song J, Xie LX, Zhang XY, Hu P, Long MF, Xiong F. et al. Role of YAP in lung cancer resistance to cisplatin. Oncol Lett. 2018;16(3):3949–54. doi: 10.3892/ol.2018.9141. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B195] 195.Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M. et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014;110(7):1698–704. doi: 10.1038/bjc.2014.95. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B196] 196.Hagenbeek TJ, Zbieg JR, Hafner M, Mroue R, Lacap JA, Sodir NM. et al. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Nat Cancer. 2023;4(6):812–28. doi: 10.1038/s43018-023-00577-0. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B197] 197.Tang TT, Konradi AW, Feng Y, Peng X, Ma M, Li J. et al. Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma. Mol Cancer Ther. 2021;20(6):986–98. doi: 10.1158/1535-7163.MCT-20-0717. [DOI] [PubMed] [Google Scholar]

[B198] 198.Kaneda A, Seike T, Danjo T, Nakajima T, Otsubo N, Yamaguchi D. et al. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma. Am J Cancer Research. 2020;10(12):4399–415. [PMC free article] [PubMed] [Google Scholar]

[B199] 199.Zagiel B, Melnyk P, Cotelle P. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present) Expert Opin Ther Pat. 2022;32(8):899–912. doi: 10.1080/13543776.2022.2096436. [DOI] [PubMed] [Google Scholar]

PERMALINK

Role of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer

Wei Zhou

Adrian Lim

Mouad Edderkaoui

Arsen Osipov

Heshui Wu

Qiang Wang

Stephen Pandol

Abstract

Current landscape of cancer therapy and challenge

The Hippo-YAP signaling pathway

YAP signaling activation and Drug Resistance

(1) YAP signaling and Chemotherapy

(2) YAP signaling and Targeted Therapy

(3) YAP signaling and Immunotherapy

YAP signaling and Programmed Cell Death

YAP signaling and Apoptosis

YAP signaling and Ferroptosis

YAP signaling and Autophagy

YAP signaling and Pyroptosis

Conclusion and Future Perspectives

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Acknowledgments

Author Contributions

ORCID

Abbreviations

References

ACTIONS

PERMALINK

RESOURCES

Cite

Add to Collections

PERMALINK

Role of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer

Wei Zhou

Adrian Lim

Mouad Edderkaoui

Arsen Osipov

Heshui Wu

Qiang Wang

Stephen Pandol

Abstract

Current landscape of cancer therapy and challenge

The Hippo-YAP signaling pathway

YAP signaling activation and Drug Resistance

(1) YAP signaling and Chemotherapy

(2) YAP signaling and Targeted Therapy

(3) YAP signaling and Immunotherapy

YAP signaling and Programmed Cell Death

YAP signaling and Apoptosis

YAP signaling and Ferroptosis

YAP signaling and Autophagy

YAP signaling and Pyroptosis

Conclusion and Future Perspectives

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Acknowledgments

Author Contributions

ORCID

Abbreviations

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases